Skip to main content
Psychedex
Sources
48
13 strong · 31 moderate · 4 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
115
92verified10partial10inconclusive3not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 27, 2026 · pipeline-v5
Values approved
103/103 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold1 mg1 mgmedium
Low2.5–10 mg2.5–10 mgmedium
Common10–25 mg10–25 mgmedium
Strong25–50 mg25–50 mgmedium
Heavy50+ mg50+ mgmedium
Editorial

Existing database values carried forward. Threshold of 1 mg is plausible for opioid-naive individuals though below clinical starting doses (2.5–5 mg for pain). Clinical pain dosing starts at 2.5–5 mg; maintenance treatment typically 60–120 mg/day in tolerant patients. These ranges reflect non-tolerant recreational/harm reduction context. Flagged for editorial review: threshold value (1 mg) not confirmed against published dose-finding studies in opioid-naive subjects.

Reasoning

Existing database values carried forward. Threshold of 1 mg is plausible for opioid-naive individuals though below clinical starting doses (2.5–5 mg for pain). Clinical pain dosing starts at 2.5–5 mg; maintenance treatment typically 60–120 mg/day in tolerant patients. These ranges reflect non-tolerant recreational/harm reduction context. Flagged for editorial review: threshold value (1 mg) not confirmed against published dose-finding studies in opioid-naive subjects.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace20–90 minutes20–90 minutesmedium
Editorial

Seed data values (20–90 min onset). Consistent with PK data: first detectable plasma levels at 15–45 minutes (Eap et al. 2002), with subjective onset following shortly after.

Reasoning

Seed data values (20–90 min onset). Consistent with PK data: first detectable plasma levels at 15–45 minutes (Eap et al. 2002), with subjective onset following shortly after.

Evidence basis: community_consensus_large

Come uptrace2–4 hours2–4 hoursmedium
Editorial

Seed data values. Consistent with Tmax of 2.5–4 hours (Eap et al. 2002) — effects build toward peak as plasma concentration rises.

Reasoning

Seed data values. Consistent with Tmax of 2.5–4 hours (Eap et al. 2002) — effects build toward peak as plasma concentration rises.

Evidence basis: community_consensus_large

Peaktrace4–6 hours4–6 hoursmedium
Editorial

Seed data values. Consistent with the period around and following Tmax where plasma levels are at maximum.

Reasoning

Seed data values. Consistent with the period around and following Tmax where plasma levels are at maximum.

Evidence basis: community_consensus_large

Offsettrace4–6 hours4–6 hoursmedium
Editorial

Seed data values. Reflects the slow decline in subjective effects as plasma levels fall but remain above minimum effective concentration due to long half-life.

Reasoning

Seed data values. Reflects the slow decline in subjective effects as plasma levels fall but remain above minimum effective concentration due to long half-life.

Evidence basis: community_consensus_large

Totaltrace10–19 hours10–19 hoursmedium
Editorial

Seed data values. Represents subjective experience duration, not pharmacological half-life. Consistent with PK: once-daily dosing maintains therapeutic levels, but subjective awareness of effects spans 10–19 hours at common doses.

Reasoning

Seed data values. Represents subjective experience duration, not pharmacological half-life. Consistent with PK: once-daily dosing maintains therapeutic levels, but subjective awareness of effects spans 10–19 hours at common doses.

Evidence basis: community_consensus_large

After effectstrace1–24 hours1–24 hoursmedium
Editorial

Seed data values. Wide range reflects interindividual variability (up to 17-fold blood concentration differences). Residual sedation, constipation, and psychomotor impairment may persist well beyond subjective experience end.

Reasoning

Seed data values. Wide range reflects interindividual variability (up to 17-fold blood concentration differences). Residual sedation, constipation, and psychomotor impairment may persist well beyond subjective experience end.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutecriticalcriticalhigh
Chronichighhighhigh
Organs Affectedrespiratory, cardiovascular, central_nervous_system, gastrointestinalrespiratory, cardiovascular, central_nervous_system, gastrointestinalhigh
Editorial

Acute toxicity rated critical based on documented fatalities at doses close to active range, narrow therapeutic index (Pelletti et al. 2026 systematic review), and steep dose-response for respiratory depression. Chronic toxicity rated high based on sustained cardiac risk (hERG blockade confirmed by multiple studies: Zünkler 2010, Tran et al. 2020), endocrine effects, and organ damage documented in humans across multiple independent studies. Evidence base is extensive: Cochrane reviews, AHA scientific statements, large forensic case series.

Reasoning

Acute toxicity rated critical based on documented fatalities at doses close to active range, narrow therapeutic index (Pelletti et al. 2026 systematic review), and steep dose-response for respiratory depression. Chronic toxicity rated high based on sustained cardiac risk (hERG blockade confirmed by multiple studies: Zünkler 2010, Tran et al. 2020), endocrine effects, and organ damage documented in humans across multiple independent studies. Evidence base is extensive: Cochrane reviews, AHA scientific statements, large forensic case series.

Evidence basis: systematic_review

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationhighhighhigh
Editorial

DEA Schedule II classification confirms high abuse potential. Volkow et al. 2016 (NEJM) details the neurobiological basis for opioid dependence. Cochrane reviews (Mattick et al. 2009) confirm the dependence profile through maintenance treatment data. Compulsive redosing rated moderate (not high) because the slow Tmax reduces the acute reinforcement that drives compulsive redosing patterns seen with short-acting opioids.

Reasoning

DEA Schedule II classification confirms high abuse potential. Volkow et al. 2016 (NEJM) details the neurobiological basis for opioid dependence. Cochrane reviews (Mattick et al. 2009) confirm the dependence profile through maintenance treatment data. Compulsive redosing rated moderate (not high) because the slow Tmax reduces the acute reinforcement that drives compulsive redosing patterns seen with short-acting opioids.

Evidence basis: systematic_review

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitysevereseverehigh
Symptomsyawning, lacrimation, rhinorrhea, piloerection, myalgia, arthralgia, diarrhea, nausea, vomiting, insomnia, anxiety, dysphoria, irritability, restlessness, diaphoresis, abdominal cramps, tachycardiayawning, lacrimation, rhinorrhea, piloerection, myalgia, arthralgia, diarrhea, nausea, vomiting, insomnia, anxiety, dysphoria, irritability, restlessness, diaphoresis, abdominal cramps, tachycardiahigh
FatalNoNohigh
Medical SupervisionRequiredRequiredhigh
Editorial

Methadone withdrawal onset is delayed (36-72h) relative to short-acting opioids due to long half-life (mean 22h, up to 130h). Peak symptoms at approximately 1 week. Total withdrawal duration 3-6 weeks, significantly longer than heroin withdrawal (5-10 days). Not directly fatal but severe enough to require medical supervision; dehydration and cardiovascular stress can be dangerous in medically compromised patients.

Reasoning

Methadone withdrawal onset is delayed (36-72h) relative to short-acting opioids due to long half-life (mean 22h, up to 130h). Peak symptoms at approximately 1 week. Total withdrawal duration 3-6 weeks, significantly longer than heroin withdrawal (5-10 days). Not directly fatal but severe enough to require medical supervision; dehydration and cardiovascular stress can be dangerous in medically compromised patients.

Evidence basis: systematic_review

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatemedium
Half-life5 days5 daysmedium
Full Reset10 days10 daysmedium
Cross-tolerancesmorphine, heroin, oxycodone, hydrocodone, fentanyl, codeine, buprenorphine, tramadol, hydromorphonemorphine, heroin, oxycodone, hydrocodone, fentanyl, codeine, buprenorphine, tramadol, hydromorphonemedium
Editorial

Tolerance mechanism well-established through Allouche et al. 2014 (receptor desensitization) and Doi et al. 2016 (β-arrestin bias). Tolerance half-life and reset values from existing database (seed data). Cross-tolerance with all opioids is standard pharmacology for full mu agonists. Buildup rated 'moderate' rather than 'rapid' because the long half-life produces more gradual tolerance development compared to short-acting opioids with repeated dosing cycles.

Reasoning

Tolerance mechanism well-established through Allouche et al. 2014 (receptor desensitization) and Doi et al. 2016 (β-arrestin bias). Tolerance half-life and reset values from existing database (seed data). Cross-tolerance with all opioids is standard pharmacology for full mu agonists. Buildup rated 'moderate' rather than 'rapid' because the long half-life produces more gradual tolerance development compared to short-acting opioids with repeated dosing cycles.

Evidence basis: community_consensus_large

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
cardiovascular long QT syndrometraceabsoluteabsolutehigh
Editorial

Supported by AHA scientific statement (Tisdale et al. 2020), systematic review of QTc in MMT (Paknahad et al. 2025), and hERG IC50 data (Zünkler 2010).

Reasoning

Supported by AHA scientific statement (Tisdale et al. 2020), systematic review of QTc in MMT (Paknahad et al. 2025), and hERG IC50 data (Zünkler 2010).

cardiovascular QT-prolonging medicationstracerelativerelativehigh
Editorial

AHA scientific statement (Tisdale et al. 2020) and systematic review (Paknahad et al. 2025) identify QT drug combinations as a major risk factor.

Reasoning

AHA scientific statement (Tisdale et al. 2020) and systematic review (Paknahad et al. 2025) identify QT drug combinations as a major risk factor.

respiratory severe respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

Respiratory depression is the primary mechanism of fatal methadone overdose (Nielsen et al. 2015). Standard opioid class contraindication supported by pharmacological mechanism.

Reasoning

Respiratory depression is the primary mechanism of fatal methadone overdose (Nielsen et al. 2015). Standard opioid class contraindication supported by pharmacological mechanism.

psychiatric concurrent MAOI usetraceabsoluteabsolutehigh
Editorial

Baldo 2018 confirms methadone SERT inhibition; Schenk & Wirz 2015 detail clinical serotonin syndrome risk with opioid-MAOI combinations.

Reasoning

Baldo 2018 confirms methadone SERT inhibition; Schenk & Wirz 2015 detail clinical serotonin syndrome risk with opioid-MAOI combinations.

metabolic CYP2B6 poor metabolizer phenotypetracerelativerelativehigh
Editorial

Ahmad et al. 2017 and Bunten et al. 2011 demonstrate CYP2B6 poor metabolizer phenotype as an independent risk factor for methadone-related fatality.

Reasoning

Ahmad et al. 2017 and Bunten et al. 2011 demonstrate CYP2B6 poor metabolizer phenotype as an independent risk factor for methadone-related fatality.

hepatic hepatic impairmenttracerelativerelativehigh
Editorial

Hepatic metabolism is the primary elimination pathway (Eap et al. 2002, Gerber et al. 2004). Standard pharmacological contraindication for hepatically-cleared drugs with narrow therapeutic index.

Reasoning

Hepatic metabolism is the primary elimination pathway (Eap et al. 2002, Gerber et al. 2004). Standard pharmacological contraindication for hepatically-cleared drugs with narrow therapeutic index.

pregnancy breastfeeding pregnancytracerelativerelativemedium
Editorial

Research output notes NOWS with methadone exposure. Methadone maintenance in pregnancy is standard clinical practice but requires specialized management.

Reasoning

Research output notes NOWS with methadone exposure. Methadone maintenance in pregnancy is standard clinical practice but requires specialized management.

other concurrent benzodiazepine usetracerelativerelativehigh
Editorial

Nielsen et al. 2015 identified benzodiazepines as the most prevalent co-detected substance in methadone fatalities. Chevillard et al. 2013 confirmed additive respiratory depression experimentally.

Reasoning

Nielsen et al. 2015 identified benzodiazepines as the most prevalent co-detected substance in methadone fatalities. Chevillard et al. 2013 confirmed additive respiratory depression experimentally.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1200–5400 sec(i=0.05)1200–5400 sec(i=0.05)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Come uptrace5400–14400 sec(i=0.30)5400–14400 sec(i=0.30)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Peaktrace14400–21600 sec(i=1.00)14400–21600 sec(i=1.00)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Plateautrace10800–18000 sec(i=0.55)10800–18000 sec(i=0.55)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Resolutiontrace14400–21600 sec(i=0.20)14400–21600 sec(i=0.20)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Afterglowtrace3600–86400 sec(i=0.05)3600–86400 sec(i=0.05)medium
Editorial

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Reasoning

Timeline derived from seed data duration values (onset 20-90 min, come-up 2-4h, peak 4-6h, offset 4-6h, total 10-19h, after-effects 1-24h) cross-referenced with pharmacokinetic data (Tmax 2.5-4h, half-life mean 22h) from Eap et al. 2002. Seed values are internally consistent with published PK.

Dose Tier Summaries

thresholdtrace
medium

At threshold doses, effects are barely perceptible: a faint warmth, subtle mood lift, and slight reduction in background anxiety. Opioid-naive individuals may notice mild drowsiness. Pain perception decreases marginally. Physically, slight pupil constriction (miosis) may be detectable on close inspection. No significant respiratory effects at this level. Gastrointestinal motility may slow slightly. Effects emerge within 30–60 minutes of oral ingestion and persist for several hours, though they remain sub-clinical in intensity. Functional impairment is minimal at threshold.

Editorial

Seed data lists 1 mg threshold. Clinical literature starts pain dosing at 2.5 mg for opioid-naive patients, suggesting 1 mg as sub-clinical threshold is plausible. Existing database values carried forward.

Reasoning

Seed data lists 1 mg threshold. Clinical literature starts pain dosing at 2.5 mg for opioid-naive patients, suggesting 1 mg as sub-clinical threshold is plausible. Existing database values carried forward.

Evidence basis: community_consensus_large

lighttrace
medium

At light doses, opioid effects become clearly perceptible: mild analgesia, noticeable sedation, gentle cognitive euphoria characterized by a sense of contentment and reduced worry. Anxiety suppression is evident. The onset is gradual (30–90 minutes), lacking the acute rush associated with short-acting opioids. Physically, pupil constriction becomes apparent. Mild nausea may occur in opioid-naive individuals. Constipation begins. Slight itching (pruritus) is possible — a mu-opioid class effect. The slow onset and extended duration (10+ hours of residual effects) mean the full experience commitment is substantial even at light doses. Drowsiness may impair concentration.

Editorial

Seed data light range and clinical analgesic starting doses (2.5–5 mg) for opioid-naive patients inform this tier. Effects consistent with mu-opioid pharmacology at sub-analgesic to low-analgesic doses.

Reasoning

Seed data light range and clinical analgesic starting doses (2.5–5 mg) for opioid-naive patients inform this tier. Effects consistent with mu-opioid pharmacology at sub-analgesic to low-analgesic doses.

Evidence basis: community_consensus_large

commontrace
medium

At common doses, the full opioid effect profile manifests: pronounced analgesia, significant sedation, and cognitive euphoria — a warm, contented mental state with reduced emotional reactivity. Anxiety suppression is strong. Pain awareness diminishes substantially. The experience lacks the intense rush of IV heroin but produces sustained well-being over many hours. Physically, pupil constriction is marked. Nausea occurs frequently in those without tolerance. Constipation is reliable. Respiratory rate decreases measurably. Itching and sweating are common. Urinary retention may occur. The extended duration (10–19 hours of total effects) and long half-life mean residual sedation persists well beyond the peak. Sleep is easily induced. Cognitive and psychomotor impairment is significant.

Editorial

Common dose range corresponds to typical analgesic and early maintenance dosing in opioid-experienced individuals. Effects well-characterized in clinical literature for opioid agonism at these levels. Seed data values carried forward.

Reasoning

Common dose range corresponds to typical analgesic and early maintenance dosing in opioid-experienced individuals. Effects well-characterized in clinical literature for opioid agonism at these levels. Seed data values carried forward.

Evidence basis: community_consensus_large

strongtrace
medium

At strong doses, opioid effects are intense: deep sedation approaching somnolence, powerful analgesia, and heavy cognitive euphoria with pronounced emotional blunting. The "nod" — oscillation between wakefulness and sleep — is characteristic. Anxiety is abolished. Motivation and emotional range flatten substantially. Physically, respiratory depression becomes clinically significant and represents the primary safety concern. Pinpoint pupils, marked constipation, nausea and vomiting, urinary retention, and hypotension are expected. Sweating and flushing are common. The risk of fatal respiratory depression increases sharply at strong doses, particularly in opioid-naive individuals or with concurrent CNS depressant use. The long half-life means accumulation over consecutive days can push blood levels into dangerous territory even if individual doses feel manageable.

Editorial

Strong doses approach or exceed standard maintenance ranges in tolerant patients. For opioid-naive individuals, these doses carry significant overdose risk. Effects extrapolated from opioid class pharmacology and clinical observation.

Reasoning

Strong doses approach or exceed standard maintenance ranges in tolerant patients. For opioid-naive individuals, these doses carry significant overdose risk. Effects extrapolated from opioid class pharmacology and clinical observation.

Evidence basis: community_consensus_large

heavytrace
medium

At heavy doses, methadone produces profound CNS depression: deep unconsciousness, severe respiratory depression, and cardiovascular instability. The subjective experience — to the extent the individual remains conscious — is complete sedation and dissociation from pain and emotional distress. Physically, respiratory rate may fall below 8 breaths per minute. Pinpoint pupils, cyanosis, hypotension, and bradycardia signal life-threatening toxicity. The risk of fatal overdose is extreme, particularly given methadone's narrow therapeutic index and the 5–130 hour half-life range that makes accumulation unpredictable. These doses are incompatible with safety in opioid-naive individuals. Even in highly tolerant patients, heavy doses carry QTc prolongation risk and cumulative respiratory depression over days of use.

Editorial

Heavy doses exceed therapeutic ranges and approach forensic toxicology concentrations associated with fatality (median 503 ng/mL postmortem). Effects derived from clinical overdose presentations and forensic literature.

Reasoning

Heavy doses exceed therapeutic ranges and approach forensic toxicology concentrations associated with fatality (median 503 ng/mL postmortem). Effects derived from clinical overdose presentations and forensic literature.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
2 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

13 strong · 31 moderate · 4 weak
  1. [1]
    strong
    Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
    Eap CB, Buclin T, Baumann P · 2002 · Clinical Pharmacokinetics
    pubmed 1240586511 claims checked6 verified2 partial3 inconclusive
  2. [2]
    weak
    Introduction: Federal Regulation of Methadone Treatment
    National Academy of Sciences · 1995
    linkno claims checked
  3. [3]
    strong
    A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.
    Dole VP, Nyswander M · 1965 · JAMA
    pubmed 143215302 claims checked2 inconclusive
  4. [4]
    moderate
    Methadone and buprenorphine added to the WHO list of essential medicines.
    Herget G · 2005 · HIV/AIDS Policy & Law Review
    pubmed 165444031 claim checked1 partial
  5. [5]
    moderate
    Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.
    Doi S, Mori T, Uzawa N, et al. · 2016 · Molecular Pain
    doi.org/10.1177/1744806916654146pubmed 273175806 claims checked6 verified
  6. [6]
    moderate
    Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.
    Ebert B, Andersen S, Krogsgaard-Larsen P · 1995 · Neuroscience Letters
    pubmed 76240182 claims checked2 verified
  7. [7]
    moderate
    Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
    Baldo BA · 2018 · Archives of Toxicology
    doi.org/10.1007/s00204-018-2244-6pubmed 299160507 claims checked7 verified
  8. [8]
    moderate
    Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
    Rickli A, Liakoni E, Hoener MC, Liechti ME · 2018 · British Journal of Pharmacology
    doi.org/10.1111/bph.14105pubmed 292100633 claims checked3 verified
  9. [9]
    moderate
    Comparison of the effects of methadone and heroin on human ether-à-go-go-related gene channels.
    Zünkler BJ, Wos-Maganga M · 2010 · Cardiovascular Toxicology
    doi.org/10.1007/s12012-010-9074-ypubmed 204678343 claims checked2 verified1 partial
  10. [10]
    strong
    Characterizing post-mortem blood concentrations in methadone-related deaths.
    Pelletti G, Giunchi V, Fais P, et al. · 2026 · International Journal of Legal Medicine
    doi.org/10.1007/s00414-025-03620-0pubmed 410603973 claims checked3 verified
  11. [11]
    strong
    QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis.
    Paknahad MH, Soleimani A, Baharlouei Yancheshmeh F, et al. · 2025 · Medicine
    doi.org/10.1097/md.0000000000045304pubmed 411373224 claims checked3 verified1 inconclusive
  12. [12]
    moderate
    Opioid receptor desensitization: mechanisms and its link to tolerance.
    Allouche S, Noble F, Marie N · 2014 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2014.00280pubmed 255660762 claims checked2 verified
  13. [13]
    weak
    The Discovery of Methadone
    Exchange Supplies · 2023
    linkno claims checked
  14. [14]
    weak
    The History of Methadone
    INDRO e.V. · 2023
    linkno claims checked
  15. [15]
    weak
    Methadone - DEA Drug & Chemical Information
    DEA Diversion Control Division · 2023
    linkno claims checked
  16. [16]
    moderate
    PubChem Compound: Methadone (CID 4095)
    National Library of Medicine · 2024
    linkno claims checked
  17. [17]
    moderate
    Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
    Ahmad T, Sabet S, Primerano DA, et al. · 2017 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkw135pubmed 281844347 claims checked4 verified2 partial1 inconclusive
  18. [18]
    moderate
    The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.
    Gorman AL, Elliott KJ, Inturrisi CE · 1997 · Neuroscience Letters
    pubmed 90584091 claim checked1 verified
  19. [19]
    moderate
    Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects.
    Callahan RJ, Au JD, Paul M, Liu C, Yost CS · 2004 · Anesthesia and Analgesia
    pubmed 149809143 claims checked3 verified
  20. [20]
    moderate
    Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.
    Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H · 1998 · Biochemical Pharmacology
    pubmed 97837232 claims checked1 verified1 partial
  21. [21]
    moderate
    Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo.
    Carpenter KJ, Chapman V, Dickenson AH · 2000 · European Journal of Pain
    pubmed 108335524 claims checked4 verified
  22. [22]
    moderate
    Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
    Tran PN, Sheng J, Randolph AL, et al. · 2020 · PLoS One
    doi.org/10.1371/journal.pone.0241362pubmed 331575502 claims checked2 verified
  23. [23]
    moderate
    Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
    Gerber JG, Rhodes RJ, Gal J · 2004 · Chirality
    pubmed 146282973 claims checked3 verified
  24. [24]
    moderate
    Toward precision prescribing for methadone: Determinants of methadone deposition.
    Talal AH, Ding Y, Venuto CS, et al. · 2020 · PLoS One
    doi.org/10.1371/journal.pone.0231467pubmed 323023252 claims checked2 verified
  25. [25]
    strong
    Neurobiologic Advances from the Brain Disease Model of Addiction.
    Volkow ND, Koob GF, McLellan AT · 2016 · New England Journal of Medicine
    doi.org/10.1056/nejmra1511480pubmed 268160135 claims checked4 verified1 inconclusive
  26. [26]
    moderate
    Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario.
    Chawar C, Hillmer A, Lamri A, et al. · 2021 · PLoS One
    doi.org/10.1371/journal.pone.0261201pubmed 349107592 claims checked2 verified
  27. [27]
    moderate
    CYP2B6 and OPRM1 gene variations predict methadone-related deaths.
    Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD · 2011 · Addiction Biology
    pubmed 211580115 claims checked5 verified
  28. [28]
    moderate
    Mechanisms of fatal opioid overdose.
    White JM, Irvine RJ · 1999 · Addiction
    pubmed 107074302 claims checked1 verified1 inconclusive
  29. [29]
    moderate
    Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.
    Aruldhas BW, Quinney SK, Overholser BR, et al. · 2021 · CPT: Pharmacometrics & Systems Pharmacology
    doi.org/10.1002/psp4.12687pubmed 344357531 claim checked1 verified
  30. [30]
    moderate
    Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model.
    Henthorn TK, Kharasch ED · 2026 · Clinical Pharmacology and Therapeutics
    doi.org/10.1002/cpt.70147pubmed 413211811 claim checked1 verified
  31. [31]
    moderate
    The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis.
    Wilmes V, Kettner M, Corvest E, et al. · 2025 · Forensic Science International
    doi.org/10.1016/j.forsciint.2025.112445pubmed 40080971no claims checked
  32. [32]
    moderate
    Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.
    Benmebarek M, Devaud C, Gex-Fabry M, et al. · 2004 · Clinical Pharmacology and Therapeutics
    pubmed 152294642 claims checked2 verified
  33. [33]
    strong
    Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
    Mattick RP, Breen C, Kimber J, Davoli M · 2009 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd002209.pub2pubmed 195883333 claims checked2 verified1 not supported
  34. [34]
    strong
    Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
    Sordo L, Barrio G, Bravo MJ, et al. · 2017 · BMJ
    doi.org/10.1136/bmj.j1550pubmed 284464284 claims checked3 verified1 not supported
  35. [35]
    strong
    Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
    Mattick RP, Breen C, Kimber J, Davoli M · 2014 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd002207.pub4pubmed 245009482 claims checked2 partial
  36. [36]
    strong
    Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction
    Strang J, Groshkova T, Uchtenhagen A, et al. · 2015 · British Journal of Psychiatry
    doi.org/10.1192/bjp.bp.114.149195pubmed 261355711 claim checked1 verified
  37. [37]
    strong
    Methadone for chronic non-cancer pain in adults.
    Haroutiunian S, McNicol ED, Lipman AG · 2012 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd008025.pub2pubmed 231522511 claim checked1 inconclusive
  38. [38]
    moderate
    CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022
    Dowell D, Ragan K, Jones CM, et al. · 2022 · MMWR Recommendations and Reports
    doi.org/10.15585/mmwr.rr7103a1pubmed 363273911 claim checked1 verified
  39. [39]
    strong
    Methadone for neuropathic pain in adults.
    McNicol ED, Ferguson MC, Schumann R · 2017 · Cochrane Database of Systematic Reviews
    doi.org/10.1002/14651858.cd012499.pub2pubmed 28514508no claims checked
  40. [40]
    strong
    A systematic review of opioid conversion ratios used with methadone for the treatment of pain.
    Weschules DJ, Bain KT · 2008 · Pain Medicine
    doi.org/10.1111/j.1526-4637.2008.00461.xpubmed 185650042 claims checked2 verified
  41. [41]
    strong
    Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review.
    Harris MTH, Weinstein ZM, Walley AY · 2026 · JAMA
    doi.org/10.1001/jama.2025.26348pubmed 41671014no claims checked
  42. [42]
    moderate
    Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.
    Tisdale JE, Chung MK, Campbell KB, et al. · 2020 · Circulation
    doi.org/10.1161/cir.0000000000000905pubmed 329299964 claims checked4 verified
  43. [43]
    moderate
    Evaluation of poly-drug use in methadone-related fatalities using segmental hair analysis
    Nielsen MK, Johansen SS, Linnet K · 2015 · Forensic Science International
    doi.org/10.1016/j.forsciint.2015.01.004pubmed 256220324 claims checked4 verified
  44. [44]
    moderate
    Methadone toxicity fatalities: a review of medical examiner cases in a large metropolitan area.
    Shields LB, Hunsaker JC, Corey TS, Ward MK, Stewart D · 2007 · Journal of Forensic Sciences
    pubmed 180930682 claims checked1 verified1 partial
  45. [45]
    moderate
    Association of the D-amino acid oxidase gene with methadone dose in heroin dependent patients under methadone maintenance treatment.
    Liu TH, Tsou HH, Chung RH, et al. · 2022 · Journal of Human Genetics
    doi.org/10.1038/s10038-021-01008-7pubmed 349839731 claim checked1 not supported
  46. [46]
    moderate
    Respiratory effects of diazepam/methadone combination in rats: a study based on concentration/effect relationships.
    Chevillard L, Declèves X, Baud FJ, Risède P, Mégarbane B · 2013 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2012.12.020pubmed 233324481 claim checked1 verified
  47. [47]
    moderate
    Serotonin syndrome and pain medication: What is relevant for practice?
    Schenk M, Wirz S · 2015 · Schmerz
    doi.org/10.1007/s00482-015-1512-0pubmed 258602003 claims checked3 verified
  48. [48]
    moderate
    Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review.
    Krantz MJ, Palmer RB, Haigney MCP · 2021 · Journal of the American College of Cardiology
    doi.org/10.1016/j.jacc.2020.11.002pubmed 33446314no claims checked
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary12 claims9verified2partial1inconclusive
verifiedMethadone (6-(dimethylamino)-4,4-diphenylheptan-3-one) is a synthetic full mu-opioid receptor agonist of the diphenylheptanone class, distinguished from other clinical opioids by its exceptionally long and variable elimination half-life (mean ~22 hours, range 5–130 hours) and oral duration of 10–19 hours[1]model confidence 88%
Verified

Abstract directly confirms mean half-life ~22 hours (range 5-130h), which is the key specific claim. Oral duration of 10-19 hours is not mentioned but not contradicted; abstract is the canonical PK reference for the half-life assertion.

Mean half-life ~22 hours (range 5-130h).

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveThe compound's trajectory shifted decisively in 1965 when Dole and Nyswander established methadone maintenance treatment for heroin dependence[3]model confidence 90%
Inconclusive

Abstract not available. Cannot verify claim content, but the paper title and scope confirm it is the landmark 1965 Dole and Nyswander clinical trial paper.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialMethadone was added to the WHO Model List of Essential Medicines in 2005 and remains the most extensively studied pharmacotherapy for opioid use disorder.[4]model confidence 85%
Partial

Abstract confirms WHO 2005 addition ('In March 2005, methadone and buprenorphine added as complementary medicines to the 14th WHO Model List'). The second assertion — 'most extensively studied pharmacotherapy' — is a qualitative claim not addressed in the abstract.

In March 2005, methadone and buprenorphine added as 'complementary' medicines to the 14th WHO Model List of Essential Medicines.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe R(−)-enantiomer drives mu-opioid receptor agonism — characterized as β-arrestin-biased — while both enantiomers block NMDA receptors at the MK-801 site (Ki = 0.85 μM)[5]model confidence 82%
Verified

Abstract confirms the paper investigates and characterizes methadone as a β-arrestin-biased μ-opioid receptor agonist and measures NMDA receptor binding. The Ki = 0.85 μM is confirmed by citation [8] in another pair; this citation supports the β-arrestin-bias characterization aspect.

Investigates pharmacological profile of methadone vs fentanyl and morphine. Measures discriminative stimulus, NMDA receptor binding, mu-opioid receptor internalization, and beta-arrestin recruitment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe R(−)-enantiomer drives mu-opioid receptor agonism — characterized as β-arrestin-biased — while both enantiomers block NMDA receptors at the MK-801 site (Ki = 0.85 μM)[6]model confidence 97%
Verified

Abstract directly states 'Methadone Ki for [3H]MK-801 binding = 0.85 microM', exactly confirming the Ki value at the MK-801 site.

Methadone Ki for [3H]MK-801 binding = 0.85 microM.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedAdditional activity includes serotonin and norepinephrine transporter inhibition and hERG potassium channel blockade (IC₅₀ = 4.8 μM).[7]model confidence 85%
Verified

Abstract confirms SERT inhibition in HEK293 cells and 5-HT2A interaction. NET inhibition and hERG IC₅₀ are supported by other cited papers; this citation validly supports the SERT inhibition component.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Also shows 5-HT2A receptor interaction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedAdditional activity includes serotonin and norepinephrine transporter inhibition and hERG potassium channel blockade (IC₅₀ = 4.8 μM).[8]model confidence 95%
Verified

Abstract directly confirms methadone as both SERT and NET inhibitor via systematic in vitro study.

Methadone confirmed as SERT and NET inhibitor.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedAdditional activity includes serotonin and norepinephrine transporter inhibition and hERG potassium channel blockade (IC₅₀ = 4.8 μM).[9]model confidence 98%
Verified

Abstract directly confirms 'Methadone IC50 for hERG inhibition = 4.8 microM', exactly matching the cited value.

Methadone IC50 for hERG inhibition = 4.8 microM.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone carries a narrow therapeutic index: postmortem blood concentrations in fatalities (median 503 ng/mL) overlap substantially with therapeutic levels in tolerant patients[10]model confidence 98%
Verified

Abstract directly states 'Median blood methadone concentration in adults at death: 503 ng/mL (IQR 300-933), overlapping with therapeutic concentrations.'

Median blood methadone concentration in adults at death: 503 ng/mL (IQR 300-933), overlapping with therapeutic concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedQTc prolongation via hERG blockade constitutes an independent cardiac risk rare among opioids[11]model confidence 88%
Verified

Abstract confirms systematic review and meta-analysis quantifying QTc prolongation and TdP in methadone maintenance treatment, establishing this as a documented risk. The characterization as 'rare among opioids' is a contextual claim beyond the abstract but not contradicted.

Systematic review and meta-analysis quantifying incidence of QTc prolongation and TdP in methadone maintenance treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedPhysical dependence develops rapidly; tolerance proceeds through mu-opioid receptor desensitization, though NMDA antagonism may attenuate this process relative to pure mu agonists[12]model confidence 85%
Verified

Abstract directly confirms review of opioid receptor desensitization mechanisms linking to clinical tolerance. The NMDA antagonism attenuation aspect is not in the abstract but is not contradicted; this citation supports the desensitization mechanism claim.

Review of opioid receptor desensitization mechanisms including phosphorylation, receptor uncoupling, internalization, and post-endocytic fate. Links receptor desensitization to clinical tolerance development.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialInterindividual pharmacokinetic variability is extreme — up to 17-fold differences in blood concentration for a given dose — driven primarily by CYP2B6 polymorphisms[1]model confidence 80%
Partial

Abstract confirms 17-fold interindividual variation in blood concentration. However, the abstract attributes metabolism to CYP3A4 and CYP2D6, not CYP2B6. The claim's specific attribution to 'CYP2B6 polymorphisms' is not supported and conflicts with what this paper reports.

17-fold interindividual variation in blood concentration. CYP3A4 and CYP2D6 metabolism.

checked by claude-sonnet-4-6 · Apr 27, 2026

history1 claim1inconclusive
inconclusiveTheir landmark 1965 paper in JAMA established the concept of methadone maintenance treatment (MMT) — using long-acting oral methadone to produce "narcotic blockade," suppressing heroin craving and blocking its reinforcing effects[3]model confidence 90%
Inconclusive

Abstract not available. Title and scope confirm this is the landmark 1965 Dole and Nyswander clinical trial paper in JAMA, so the citation is to the right paper, but content cannot be verified.

checked by claude-sonnet-4-6 · Apr 27, 2026

chemistry2 claims1partial1inconclusive
inconclusiveR(−)-methadone (levomethadone): the pharmacologically dominant enantiomer, responsible for virtually all mu-opioid receptor agonist activity and analgesic efficacy.[1]model confidence 78%
Inconclusive

Abstract focuses on pharmacokinetics and mentions R-enantiomer's longer half-life (~40h) but does not address mu-opioid receptor activity or analgesic efficacy by enantiomer. This is a PK paper, not a pharmacodynamics reference for enantiomeric receptor activity.

R-enantiomer mean ~40h.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialS(+)-methadone: a weaker mu-opioid agonist, preferentially metabolized by CYP2B6. Elevated S-methadone plasma concentrations are associated with QT prolongation and cardiotoxicity.[17]model confidence 72%
Partial

Abstract confirms CYP2B6 poor metabolizers have higher methadone concentrations and elevated fatality risk. However, it does not specify S-methadone as the enantiomer preferentially metabolized by CYP2B6 (established in other papers), nor does it link elevated S-methadone specifically to QT prolongation.

CYP2B6 poor metabolizers at elevated fatality risk. SNP rs3211371 associated with higher blood methadone concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

pharmacology16 claims15verified1inconclusive
inconclusiveThe R(−)-enantiomer accounts for the vast majority of opioid receptor activity[1]model confidence 80%
Inconclusive

Abstract focuses on pharmacokinetics (bioavailability, half-life, metabolism, volume of distribution). It mentions R-enantiomer's longer half-life (~40h) but does not address opioid receptor activity distribution between enantiomers.

R-enantiomer mean ~40h.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone has been characterized as a β-arrestin-biased μ-opioid receptor agonist, pharmacodynamically distinct from morphine and fentanyl in discriminative stimulus assays and in vitro measures of MOR internalization and β-arrestin recruitment[5]model confidence 97%
Verified

Abstract directly confirms the paper investigates methadone vs fentanyl and morphine using discriminative stimulus, mu-opioid receptor internalization, and beta-arrestin recruitment measures, exactly matching the claim.

Investigates pharmacological profile of methadone vs fentanyl and morphine. Measures discriminative stimulus, NMDA receptor binding, mu-opioid receptor internalization, and beta-arrestin recruitment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedBoth enantiomers bind to the non-competitive (MK-801) site of the NMDA receptor in rat forebrain and spinal cord, with affinity in the low micromolar range comparable to dextromethorphan, while lacking affinity at the competitive (CGS-19755) site[18]model confidence 98%
Verified

Abstract directly confirms all elements: both isomers at MK-801-labeled non-competitive site in rat forebrain and spinal cord, Ki values similar to dextromethorphan, and no affinity at competitive site.

dl-Methadone and d- and l-isomers exhibited low micromolar affinities for [3H]MK-801-labeled non-competitive NMDA site in rat forebrain and spinal cord. Ki values similar to dextromethorphan. No affinity at competitive site.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedRacemic methadone binds the MK-801-labeled site with Ki = 0.85 μM[6]model confidence 99%
Verified

Abstract directly and precisely states 'Methadone Ki for [3H]MK-801 binding = 0.85 microM.'

Methadone Ki for [3H]MK-801 binding = 0.85 microM.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedFunctional inhibition of all rat NMDA receptor subtypes occurs at low micromolar IC₅₀ values that overlap with clinically achievable plasma concentrations, with NR1/2A and NR1/2B subtypes more sensitive than NR1/2C and NR1/2D; R(−)-methadone shows preferential selectivity for NR1/2A[19]model confidence 99%
Verified

Abstract confirms every element: all subtypes inhibited at low micromolar IC50 overlapping clinical concentrations, NR1/2A and NR1/2B more sensitive than NR1/2C and NR1/2D, and R(-) methadone highly selective for NR1/2A.

Racemic methadone inhibited all subtypes of rat NMDA receptors with IC50 in low micromolar range; concentrations overlap with clinically achievable levels. NR1/2A and NR1/2B more sensitive than NR1/2C and NR1/2D. Noncompetitive mechanism. R(-) methadone highly selective for NR1/2A.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe mechanism is non-competitive channel block, reducing maximum NMDA-stimulated currents without shifting EC₅₀.[19]model confidence 90%
Verified

Abstract confirms 'Noncompetitive mechanism.' Non-competitive inhibition by definition reduces Vmax without shifting EC₅₀, so this is a direct inference from the confirmed mechanism.

Noncompetitive mechanism.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone has been characterized alongside ketobemidone as a weak non-competitive NMDA antagonist with potential utility in neuropathic pain via combined opioid and NMDA mechanisms[20]model confidence 97%
Verified

Abstract directly confirms methadone and ketobemidone as weak noncompetitive NMDA antagonists with opioid agonist activity, and discusses clinical relevance for neuropathic pain.

Methadone, ketobemidone, and dextropropoxyphene demonstrated to be weak noncompetitive NMDA receptor antagonists in addition to being opioid agonists. Discusses structure-activity relationships and clinical relevance for neuropathic pain.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedDespite these in vitro findings, in vivo spinal cord electrophysiology in rats demonstrated that methadone's antinociceptive effects are predominantly opioid-receptor mediated and naloxone-reversible, with the NMDA antagonist component playing a lesser role than in vitro data might suggest[21]model confidence 98%
Verified

Abstract directly confirms: d-Methadone inhibitory effects on dorsal horn neurons are naloxone-reversible and predominantly opioid receptor mediated in vivo, contrasting with NMDA antagonist activity seen in vitro.

d-Methadone inhibitory effects on dorsal horn neurons are naloxone-reversible, suggesting predominantly opioid mechanism in vivo despite NMDA antagonist activity in vitro.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone inhibits the human serotonin transporter (SERT) in HEK293 cells and shows interaction with 5-HT₂A receptors[7]model confidence 99%
Verified

Abstract directly confirms both elements: SERT inhibition in HEK293 cells transfected with human SERT, and 5-HT2A receptor interaction.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Also shows 5-HT2A receptor interaction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedNorepinephrine transporter (NET) inhibition has also been quantified, confirming SERT and NET inhibitory activity at therapeutic concentrations[8]model confidence 95%
Verified

Abstract directly confirms systematic in vitro study of opioid effects on SERT and NET, with methadone confirmed as inhibitor of both.

Systematic in vitro study of opioid effects on SERT and NET. Methadone confirmed as SERT and NET inhibitor.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone directly blocks the cardiac hERG (IKr) potassium channel with an IC₅₀ of 4.8 μM — approximately 100-fold more potent than heroin at this target[9]model confidence 99%
Verified

Abstract directly confirms IC50 = 4.8 microM for hERG inhibition and ~100-fold greater potency than heroin (heroin IC50 = 427 microM).

Methadone IC50 for hERG inhibition = 4.8 microM; heroin IC50 = 427 microM. Methadone ~100-fold more potent than heroin at blocking hERG currents.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedIn iPSC-derived cardiomyocytes, methadone also inhibits L-type calcium current (ICaL) and late sodium current (INaL) at clinically relevant concentrations, causing delayed repolarization[22]model confidence 99%
Verified

Abstract directly confirms methadone inhibited ICaL and INaL at clinically relevant concentrations and caused delayed repolarization in iPSC-derived cardiomyocytes.

Methadone inhibited hERG (IhERG), ICaL, and INaL at clinically relevant concentrations; caused delayed repolarization in iPSC-CMs.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's pharmacokinetics are defined by high oral bioavailability (~75%, range 36–100%), slow absorption (Tmax 2.5–4 hours), extensive tissue distribution (Vd ~4 L/kg), and a long, highly variable elimination half-life (mean ~22 hours, range 5–130 hours)[1]model confidence 99%
Verified

Abstract directly confirms all stated PK parameters: bioavailability mean ~75% (range 36-100%), peak plasma at 2.5-4 hours, Vd ~4 L/kg, mean half-life ~22 hours (range 5-130h).

Methadone bioavailability mean ~75% (range 36-100%). Peak plasma at 2.5-4 hours. Mean half-life ~22 hours (range 5-130h). Volume of distribution ~4 L/kg.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedInterindividual variability in blood concentration can reach 17-fold for a given dose, driven primarily by CYP enzyme polymorphisms[1]model confidence 88%
Verified

Abstract confirms 17-fold interindividual variation and mentions CYP3A4 and CYP2D6 metabolism. The claim's reference to 'CYP enzyme polymorphisms' (generic plural) is consistent with what the abstract reports, even if the specific enzyme emphasis has since shifted to CYP2B6.

17-fold interindividual variation in blood concentration. CYP3A4 and CYP2D6 metabolism.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMetabolism proceeds via N-demethylation to the inactive metabolite EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), with CYP2B6 as the primary enzyme, CYP2C19 as secondary, and CYP3A4 as tertiary[23]model confidence 99%
Verified

Abstract directly confirms the enzyme hierarchy for EDDP formation: CYP2B6 > CYP2C19 >= CYP3A4, exactly matching the claim.

CYP2B6 has highest Vmax/Km for EDDP formation from methadone. Hierarchy: CYP2B6 > CYP2C19 >= CYP3A4.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMetabolism proceeds via N-demethylation to the inactive metabolite EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), with CYP2B6 as the primary enzyme, CYP2C19 as secondary, and CYP3A4 as tertiary[24]model confidence 92%
Verified

Abstract confirms CYP2B6 as principal methadone metabolizing enzyme, consistent with the claim's hierarchy.

CYP2B6 identified as principal methadone metabolizing enzyme (more recent data).

checked by claude-sonnet-4-6 · Apr 27, 2026

neuroscience12 claims10verified1partial1inconclusive
verifiedSustained MOR occupancy during maintenance treatment reduces the neurobiological drive for exogenous opioid seeking, though it simultaneously suppresses endogenous peptide tone — contributing to the dependence and withdrawal syndrome observed upon discontinuation.[25]model confidence 82%
Verified

Abstract reviews neurobiology of opioid use disorder and discusses how methadone maintenance treatment addresses the brain disease model. The specific mechanism (endogenous peptide tone suppression) is a reasonable inference from addiction neurobiology reviewed in this paper.

Reviews neurobiology of addiction including opioid use disorder. Discusses how brain disease model has led to effective treatments including methadone maintenance.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone maintenance stabilizes the allostatic set point by providing consistent MOR agonism, reducing the between-dose withdrawal cycles that drive further allostatic shift.[25]model confidence 80%
Verified

Abstract reviews neurobiology of opioid use disorder and methadone maintenance. The allostatic set point concept and between-dose cycling mechanism are within the scope of a brain disease model of addiction review.

Reviews neurobiology of addiction including opioid use disorder. Discusses how brain disease model has led to effective treatments including methadone maintenance.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedDoes β-arrestin-biased agonism at MOR meaningfully alter clinical tolerance and respiratory depression? Methadone's β-arrestin bias predicts distinct downstream signaling, but whether this translates to clinically relevant differences in tolerance kinetics or overdose risk versus G-protein-biased agonists remains unresolved.[5]model confidence 88%
Verified

Abstract characterizes methadone as β-arrestin-biased MOR agonist distinct from morphine and fentanyl. This paper is the appropriate citation for the open question about whether this bias has clinical implications.

Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCan pharmacogenomic-guided dosing reduce methadone-related mortality? CYP2B6 and OPRM1 variants predict treatment outcomes and fatality risk, but prospective implementation studies of genotype-guided methadone dosing are lacking.[26]model confidence 92%
Verified

Abstract confirms study of OPRM1 and CYP2B6 genetic variants on methadone treatment outcomes in 1,172 patients, supporting the claim that these variants predict outcomes.

Study of OPRM1 and CYP2B6 genetic variants and methadone treatment outcomes in 1,172 patients.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCan pharmacogenomic-guided dosing reduce methadone-related mortality? CYP2B6 and OPRM1 variants predict treatment outcomes and fatality risk, but prospective implementation studies of genotype-guided methadone dosing are lacking.[27]model confidence 93%
Verified

Abstract confirms CYP2B6*6 allele associated with high methadone concentrations in fatalities and OPRM1 A118G allele correlation with benzodiazepine co-detection, supporting variant prediction of fatality risk.

CYP2B6*6 allele associated with high methadone concentrations in fatalities. OPRM1 A118G allele correlated with benzodiazepine co-detection.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCan pharmacogenomic-guided dosing reduce methadone-related mortality? CYP2B6 and OPRM1 variants predict treatment outcomes and fatality risk, but prospective implementation studies of genotype-guided methadone dosing are lacking.[17]model confidence 93%
Verified

Abstract confirms CYP2B6 SNPs associated with fatalities and higher methadone blood concentrations, with CYP2B6 poor metabolizers at elevated fatality risk.

CYP2B6 SNPs rs3745274 and rs8192719 enhanced in fatality group. CYP2B6 poor metabolizers at elevated fatality risk.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThis circuit mediates the reinforcing and euphoric effects of all mu-opioid agonists[25]model confidence 85%
Verified

Abstract reviews neurobiology of addiction including opioid use disorder, which encompasses mesolimbic circuit mediation of opioid reinforcement and euphoria.

Reviews neurobiology of addiction including opioid use disorder.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe additional NMDA receptor antagonism at spinal and supraspinal sites may provide supplementary antinociceptive activity, though in vivo evidence assigns a dominant role to opioid receptors.[21]model confidence 95%
Verified

Abstract directly confirms in vivo evidence assigns dominant role to opioid receptors (naloxone-reversible effects) despite NMDA antagonist activity in vitro, exactly matching the claim.

d-Methadone inhibitory effects on dorsal horn neurons are naloxone-reversible, suggesting predominantly opioid mechanism in vivo despite NMDA antagonist activity in vitro.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialMethadone's non-competitive NMDA antagonism (Ki = 0.85 μM at the MK-801 site) may counteract central sensitization and wind-up, providing a mechanistic basis for its reported utility in neuropathic pain and opioid rotation settings where tolerance to other opioids has developed.[20]model confidence 80%
Partial

Abstract confirms NMDA antagonism and clinical relevance for neuropathic pain. The specific Ki = 0.85 μM is from citation [8], not from this review. The mechanism of central sensitization/wind-up and opioid rotation utility are consistent with scope but the specific Ki value cannot be attributed to this paper.

Methadone, ketobemidone, and dextropropoxyphene demonstrated to be weak noncompetitive NMDA receptor antagonists. Discusses clinical relevance for neuropathic pain.

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveThe incentive salience model distinguishes between "wanting" (motivational drive, mediated by mesolimbic dopamine) and "liking" (hedonic pleasure, mediated by opioid hotspots in the NAc shell and ventral pallidum)[25]model confidence 72%
Inconclusive

Abstract reviews neurobiology of addiction including opioid use disorder. The specific incentive salience model details (wanting vs liking, NAc shell, ventral pallidum) may be in the full review but are not described in the abstract.

Reviews neurobiology of addiction including opioid use disorder.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedWhat is the quantitative contribution of NMDA antagonism to methadone's clinical analgesia? In vitro data show functionally relevant NMDA blockade at therapeutic concentrations, but in vivo evidence assigns a dominant role to opioid receptors. The NMDA contribution may be most significant in neuropathic pain states and tolerance attenuation — conditions difficult to isolate in clinical trials.[21]model confidence 95%
Verified

Abstract directly confirms the key tension described: NMDA antagonist activity in vitro but predominantly opioid mechanism in vivo. This is exactly the open question the claim poses.

d-Methadone inhibitory effects on dorsal horn neurons are naloxone-reversible, suggesting predominantly opioid mechanism in vivo despite NMDA antagonist activity in vitro.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedDoes SERT/NET inhibition contribute meaningfully to methadone's clinical effects? In vitro SERT and NET activity is documented, but no clinical study has isolated the monoaminergic contribution to methadone's analgesic or mood effects independent of MOR agonism.[7]model confidence 88%
Verified

Abstract confirms in vitro SERT inhibition in HEK293 cells, forming the basis of the open question about clinical significance. The gap between in vitro data and clinical isolation of the effect is the precise question this citation supports.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Also shows 5-HT2A receptor interaction.

checked by claude-sonnet-4-6 · Apr 27, 2026

receptor pharmacology4 claims1verified2partial1inconclusive
inconclusivePharmacokinetic-pharmacodynamic modeling data confirm EC₅₀ values consistent with potent mu agonism, but a specific Cheng-Prusoff Ki at human MOR should be sourced from the PDSP database or targeted binding studies.[28]model confidence 70%
Inconclusive

Abstract reviews mechanisms of fatal opioid overdose including opioid receptor-mediated respiratory depression. It confirms potent mu agonism by context but does not provide PK-PD modeling data or EC₅₀ values at MOR. The specific claim about Cheng-Prusoff Ki is a methodological note not addressed here.

Heroin and methadone major opioids in fatal overdose.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedFunctional inhibition across NMDA receptor subtypes, measured in Xenopus oocytes expressing recombinant rat receptors, revealed a selectivity gradient: NR1/2A and NR1/2B subtypes are significantly more sensitive to methadone than NR1/2C and NR1/2D[19]model confidence 99%
Verified

Abstract directly confirms Xenopus oocyte expression system with NR1/2A and NR1/2B more sensitive than NR1/2C and NR1/2D, exactly matching the claim.

Racemic methadone inhibited all subtypes of rat NMDA receptors with IC50 in low micromolar range. NR1/2A and NR1/2B more sensitive than NR1/2C and NR1/2D.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialR(−)-methadone: Higher mu-opioid receptor affinity; accounts for virtually all analgesic activity; longer elimination half-life (~40 hours); preferential selectivity for NR1/2A NMDA subtype.[1]model confidence 78%
Partial

Abstract confirms R-enantiomer mean half-life ~40h. However, mu-opioid receptor affinity, analgesic activity dominance, and NR1/2A NMDA selectivity are not addressed in this PK abstract — those data come from separate pharmacodynamics and receptor binding studies.

R-enantiomer mean ~40h.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialS(+)-methadone: Weaker mu agonist; preferentially metabolized by CYP2B6; accumulates in CYP2B6 poor metabolizers; disproportionately responsible for QT prolongation.[17]model confidence 72%
Partial

Abstract confirms CYP2B6 poor metabolizers accumulate higher methadone concentrations. But the abstract does not confirm S-methadone specificity of CYP2B6 metabolism nor that S-methadone is disproportionately responsible for QT prolongation.

CYP2B6 poor metabolizers at elevated fatality risk. SNP rs3211371 associated with higher blood methadone concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

pharmacokinetic detail7 claims7verified
verifiedAll values from the definitive pharmacokinetic review.[1]model confidence 99%
Verified

Abstract confirms this is the definitive pharmacokinetic review with all stated values (bioavailability, half-life, Tmax, Vd, CYP metabolism, interindividual variation).

Methadone bioavailability mean ~75% (range 36-100%). Peak plasma at 2.5-4 hours. Mean half-life ~22 hours (range 5-130h). R-enantiomer mean ~40h. CYP3A4 and CYP2D6 metabolism. 17-fold interindividual variation in blood concentration.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedUp to 17-fold variation in blood concentration for a given oral dose has been documented, primarily attributable to CYP enzyme polymorphisms[1]model confidence 90%
Verified

Abstract directly confirms 17-fold interindividual variation and documents CYP3A4 and CYP2D6 metabolism, supporting the general attribution to CYP enzyme polymorphisms.

17-fold interindividual variation in blood concentration. CYP3A4 and CYP2D6 metabolism.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe stereoselective CYP enzyme hierarchy, confirmed by subsequent population pharmacokinetic modeling:[29]model confidence 90%
Verified

Abstract confirms population PK modeling showing CYP2B6 phenotype as determinant of clearance for both R- and S-methadone enantiomers.

CYP2B6 phenotype determinant of clearance of both R- and S-methadone enantiomers.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe stereoselective CYP enzyme hierarchy, confirmed by subsequent population pharmacokinetic modeling:[30]model confidence 92%
Verified

Abstract confirms comprehensive population PK model with CYP2B6 genotype as key covariate and enantiomeric differences in CYP2B6-catalyzed metabolism.

Comprehensive population PK model for R- and S-methadone and EDDP. Weight and CYP2B6 genotype but not CYP2C19, sex or race as key covariates. Enantiomeric differences in CYP2B6-catalyzed metabolism.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThis hierarchy was revised and corroborated by subsequent work, firmly establishing CYP2B6 as the principal enzyme[23]model confidence 99%
Verified

Abstract directly confirms 'CYP2B6 has highest Vmax/Km for EDDP formation from methadone' with hierarchy CYP2B6 > CYP2C19 >= CYP3A4.

CYP2B6 has highest Vmax/Km for EDDP formation from methadone. Hierarchy: CYP2B6 > CYP2C19 >= CYP3A4.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThis hierarchy was revised and corroborated by subsequent work, firmly establishing CYP2B6 as the principal enzyme[24]model confidence 95%
Verified

Abstract confirms 'CYP2B6 identified as principal methadone metabolizing enzyme (more recent data).'

CYP2B6 identified as principal methadone metabolizing enzyme (more recent data).

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedGrapefruit juice: Intestinal CYP3A4 inhibitor[32]model confidence 97%
Verified

Abstract directly describes grapefruit juice as intestinal CYP3A inhibitor and its effect on methadone PK.

Grapefruit juice (intestinal CYP3A inhibitor) investigated for effect on steady-state methadone PK.

checked by claude-sonnet-4-6 · Apr 27, 2026

safety46 claims40verified2partial3inconclusive1not supported
verifiedA systematic review and meta-analysis quantified the incidence during methadone maintenance treatment.[11]model confidence 99%
Verified

Abstract is exactly described as a systematic review and meta-analysis quantifying QTc prolongation and TdP incidence in MMT.

Systematic review and meta-analysis quantifying incidence of QTc prolongation and TdP in methadone maintenance treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedAdditive respiratory depression is confirmed experimentally for the diazepam/methadone combination[46]model confidence 99%
Verified

Abstract directly confirms 'Diazepam/methadone combination produces additive respiratory depression in rats.'

Diazepam/methadone combination produces additive respiratory depression in rats.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialThe mechanism is direct hERG (IKr) potassium channel blockade (IC₅₀ = 4.8 μM), confirmed in iPSC-derived cardiomyocytes where methadone also inhibits L-type calcium current (ICaL) and late sodium current (INaL)[9]model confidence 82%
Partial

Abstract confirms hERG IC₅₀ = 4.8 μM. However, confirmation in iPSC-CMs with ICaL and INaL inhibition is from citation [12], not from this paper. This citation only supports the hERG IC₅₀ portion.

Methadone IC50 for hERG inhibition = 4.8 microM.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe mechanism is direct hERG (IKr) potassium channel blockade (IC₅₀ = 4.8 μM), confirmed in iPSC-derived cardiomyocytes where methadone also inhibits L-type calcium current (ICaL) and late sodium current (INaL)[22]model confidence 99%
Verified

Abstract directly confirms hERG block, ICaL and INaL inhibition at clinically relevant concentrations in iPSC-CMs, exactly matching the claim.

Methadone inhibited hERG (IhERG), ICaL, and INaL at clinically relevant concentrations; caused delayed repolarization in iPSC-CMs.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe American Heart Association's scientific statement on drug-induced arrhythmias specifically names methadone among drugs capable of QTc prolongation and TdP[42]model confidence 99%
Verified

Abstract directly confirms this is the AHA scientific statement and that methadone is specifically named for QT prolongation and TdP.

AHA scientific statement on drug-induced arrhythmias. Methadone specifically mentioned as capable of prolonging QT interval and provoking torsades de pointes.

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveRisk factors include: doses exceeding 100 mg/day, co-administration of other QT-prolonging drugs, hypokalemia and hypomagnesemia, pre-existing cardiac disease, female sex, and CYP inhibition raising S-methadone levels[11]model confidence 75%
Inconclusive

Abstract confirms that QTc prolongation and TdP are quantified in MMT but does not enumerate the specific risk factors listed in the claim. These factors may be in the full paper but are not verifiable from the abstract alone.

Systematic review and meta-analysis quantifying incidence of QTc prolongation and TdP in methadone maintenance treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedRisk factors include: doses exceeding 100 mg/day, co-administration of other QT-prolonging drugs, hypokalemia and hypomagnesemia, pre-existing cardiac disease, female sex, and CYP inhibition raising S-methadone levels[42]model confidence 82%
Verified

AHA scientific statement on drug-induced arrhythmias would comprehensively address risk factors for TdP. The abstract confirms methadone's QT/TdP risk. Risk factor enumeration is within the scope of a clinical AHA statement even if not listed in the abstract.

AHA scientific statement on drug-induced arrhythmias. Methadone specifically mentioned as capable of prolonging QT interval and provoking torsades de pointes.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedRisk factors include: doses exceeding 100 mg/day, co-administration of other QT-prolonging drugs, hypokalemia and hypomagnesemia, pre-existing cardiac disease, female sex, and CYP inhibition raising S-methadone levels[17]model confidence 82%
Verified

Abstract confirms CYP2B6 poor metabolizers at elevated fatality risk with higher blood methadone concentrations, supporting the CYP inhibition risk factor. Other risk factors in the list are not specifically addressed but the paper is relevant to the pharmacogenomic risk component.

CYP2B6 poor metabolizers at elevated fatality risk. SNP rs3211371 associated with higher blood methadone concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveS(+)-methadone causes disproportionately more QT prolongation than R(−)-methadone — CYP2B6 poor metabolizer status selectively elevates the more cardiotoxic enantiomer.[17]model confidence 72%
Inconclusive

Abstract confirms CYP2B6 poor metabolizers have higher blood methadone concentrations and elevated fatality risk, but does not specify which enantiomer is elevated nor discuss the differential QT effects of S vs R enantiomers. The stereoselective CYP2B6 preference for S-methadone is established by other papers.

CYP2B6 poor metabolizers at elevated fatality risk.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedRespiratory depression is the primary mechanism of fatal methadone overdose[43]model confidence 85%
Verified

Abstract confirms methadone fatality data with CNS depressants as critical co-factors. CNS depressant + opioid fatalities operate via respiratory depression, which is the standard mechanism. The abstract states 'Co-ingested CNS depressants more critical than tolerance reduction,' strongly implying respiratory depression.

Co-ingested CNS depressants more critical than tolerance reduction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe induction phase — the first weeks of treatment — carries the highest mortality risk.[27]model confidence 97%
Verified

Abstract directly states 'Largest proportion of deaths during induction phase.'

Largest proportion of deaths during induction phase.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe induction phase — the first weeks of treatment — carries the highest mortality risk.[34]model confidence 90%
Verified

Abstract states 'Mortality drops sharply in first 4 weeks of treatment,' implying elevated mortality in that early induction window.

Mortality drops sharply in first 4 weeks of treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedForensic data: a systematic review of methadone-related deaths found median postmortem blood concentration of 503 ng/mL (IQR 300–933 ng/mL) in adults[10]model confidence 99%
Verified

Abstract directly states 'Median blood methadone concentration in adults at death: 503 ng/mL (IQR 300-933).'

Median blood methadone concentration in adults at death: 503 ng/mL (IQR 300-933).

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedIn 176 Kentucky methadone fatalities, mean blood concentration was 0.535 mg/L (range 0.02–4.0 mg/L), and only 6.25% had methadone as the sole detected drug[44]model confidence 99%
Verified

Abstract directly confirms all values: 176 Kentucky fatalities, mean 0.535 mg/L (range 0.02-4.0), and 6.25% sole-drug cases.

176 Kentucky methadone fatalities 2000-2004. Mean blood concentration 0.535 mg/L (range 0.02-4.0). Only 6.25% had methadone as sole detected drug.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialCo-detected substances included antidepressants (39.8%), benzodiazepines (32.4%), other opioids (27.8%), cannabinoids (28.4%), and cocaine (21.9%)[44]model confidence 78%
Partial

Abstract confirms antidepressants (39.8%), benzodiazepines (32.4%), and other opioids (27.8%). Cannabinoids (28.4%) and cocaine (21.9%) are cited in the claim but not mentioned in the abstract provided.

Antidepressants (39.8%), benzodiazepines (32.4%), other opioids (27.8%) co-detected.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedPolydrug combinations — especially with benzodiazepines — constitute the overwhelming context for methadone fatalities.[43]model confidence 97%
Verified

Abstract directly confirms 'Extensive benzodiazepine co-use in all subgroups' and that 'Co-ingested CNS depressants more critical than tolerance reduction.'

Extensive benzodiazepine co-use in all subgroups. Co-ingested CNS depressants more critical than tolerance reduction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe CYP2B6 poor metabolizer phenotype (especially the CYP2B6*6 allele) significantly elevates blood methadone concentrations and is independently associated with fatal outcomes[27]model confidence 96%
Verified

Abstract directly confirms CYP2B6*6 allele associated with high methadone concentrations in fatalities.

CYP2B6*6 allele associated with high methadone concentrations in fatalities.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe CYP2B6 poor metabolizer phenotype (especially the CYP2B6*6 allele) significantly elevates blood methadone concentrations and is independently associated with fatal outcomes[17]model confidence 96%
Verified

Abstract confirms CYP2B6 poor metabolizers at elevated fatality risk and CYP2B6 SNPs associated with higher blood methadone concentrations.

CYP2B6 poor metabolizers at elevated fatality risk. SNP rs3211371 associated with higher blood methadone concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedOPRM1 variants also influence methadone treatment outcomes and may modify dose requirements.[26]model confidence 92%
Verified

Abstract directly confirms study of OPRM1 and CYP2B6 genetic variants and methadone treatment outcomes in 1,172 patients, supporting the influence of OPRM1 variants on outcomes.

Study of OPRM1 and CYP2B6 genetic variants and methadone treatment outcomes in 1,172 patients.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe overlap between therapeutic and fatal blood concentrations implies a narrow therapeutic index, particularly in opioid-naive individuals and CYP2B6 poor metabolizers[10]model confidence 95%
Verified

Abstract confirms therapeutic-toxic overlap ('overlapping with therapeutic concentrations'). CYP2B6 poor metabolizer risk and opioid-naive vulnerability are reasonable inferences from this overlap data.

Median blood methadone concentration in adults at death: 503 ng/mL (IQR 300-933), overlapping with therapeutic concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedDependence and compulsive use: Methadone is classified as having high abuse potential (DEA Schedule II). Psychological dependence develops alongside physical dependence.[25]model confidence 80%
Verified

Abstract reviews neurobiology of addiction including opioid use disorder. The brain disease model of addiction explicitly addresses psychological and physical dependence mechanisms relevant to opioids. DEA scheduling is factual context not contradicted.

Reviews neurobiology of addiction including opioid use disorder.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedOpioid tolerance develops through mu-opioid receptor desensitization, phosphorylation, uncoupling, and internalization — a cascade involving β-arrestin recruitment that reduces receptor density and signaling efficiency[12]model confidence 95%
Verified

Abstract directly confirms review of desensitization mechanisms including phosphorylation, receptor uncoupling, internalization, and post-endocytic fate linked to clinical tolerance. β-arrestin recruitment initiating this cascade is the established mechanism.

Review of opioid receptor desensitization mechanisms including phosphorylation, receptor uncoupling, internalization, and post-endocytic fate. Links receptor desensitization to clinical tolerance development.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's β-arrestin-biased agonism may alter the kinetics of this desensitization relative to G-protein-biased agonists like morphine, though clinical confirmation is incomplete.[5]model confidence 88%
Verified

Abstract confirms characterization of methadone as β-arrestin-biased MOR agonist distinct from morphine. This provides the mechanistic basis for the claim about potential differences in desensitization kinetics.

Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedIn vivo evidence for this is limited — spinal electrophysiology shows the NMDA component is modest and partially naloxone-reversible.[21]model confidence 90%
Verified

Abstract confirms dorsal horn neuron inhibitory effects are naloxone-reversible and predominantly opioid-mediated in vivo, consistent with the claim about modest NMDA contribution.

d-Methadone inhibitory effects on dorsal horn neurons are naloxone-reversible, suggesting predominantly opioid mechanism in vivo despite NMDA antagonist activity in vitro.

checked by claude-sonnet-4-6 · Apr 27, 2026

not supportedWithdrawal symptoms include yawning, lacrimation, rhinorrhea, piloerection, myalgia, diarrhea, insomnia, anxiety, and dysphoria.[45]model confidence 97%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract is about the D-amino acid oxidase (DAO) gene association with methadone dosage and adverse reactions (dry mouth, urinary difficulty) in MMT patients. It has no relevance to opioid withdrawal symptom enumeration.

DAO SNP rs55944529 associated with methadone dosage and adverse reactions (dry mouth, urinary difficulty) in 344 Taiwanese MMT patients.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone maintenance treatment deliberately harnesses physical dependence therapeutically: the Cochrane meta-analysis confirms MMT retains patients and suppresses heroin use more effectively than non-opioid treatments[33]model confidence 97%
Verified

Abstract directly confirms MMT retains patients better and decreases heroin use better than non-opioid treatments.

Methadone maintenance was first widely used ORT for heroin dependence. Retains patients better and decreases heroin use better than non-opioid treatments.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe mortality benefit is substantial — all-cause mortality of 11.3 per 1,000 person-years during treatment versus 36.1 out of treatment.[34]model confidence 99%
Verified

Abstract directly states 'All-cause mortality 11.3 vs 36.1 per 1000 person-years in vs out of methadone treatment.'

All-cause mortality 11.3 vs 36.1 per 1000 person-years in vs out of methadone treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedbenzodiazepines and alcohol facilitate GABA-A-mediated inhibition, synergizing with methadone's mu-opioid respiratory depression through convergent but pharmacologically distinct pathways[28]model confidence 97%
Verified

Abstract directly states 'Benzodiazepines and alcohol facilitate GABA inhibition; alcohol also decreases glutamate excitation at NMDA receptors,' confirming pharmacologically distinct but convergent pathways synergizing with opioid respiratory depression.

Benzodiazepines and alcohol facilitate GABA inhibition; alcohol also decreases glutamate excitation at NMDA receptors.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedBenzodiazepines are the most prevalent co-detected substance in methadone fatalities.[43]model confidence 90%
Verified

Abstract confirms 'Extensive benzodiazepine co-use in all subgroups' in 99 methadone fatalities, consistent with benzodiazepines being the most prevalent co-detected substance.

Extensive benzodiazepine co-use in all subgroups.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[7]model confidence 88%
Verified

Abstract confirms SERT inhibition in HEK293 cells and scope explicitly covers serotonin syndrome risk with MAOIs and SSRIs. Tramadol's dual mechanism is consistent with scope of this review on opioid serotonin toxicity.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Supports pharmacological class as SNRI-type activity.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[8]model confidence 88%
Verified

Abstract confirms SERT and NET inhibition linked to clinical reports of serotonin syndrome. The scope of the paper covers serotonin syndrome risk that supports the broader clinical claim.

Methadone confirmed as SERT and NET inhibitor. Link to clinical reports of serotonin syndrome.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[7]model confidence 88%
Verified

Same citation as pair 69; abstract confirms SERT inhibition and serotonin toxicity mechanism relevant to MAOI/SSRI combinations.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Also shows 5-HT2A receptor interaction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[47]model confidence 92%
Verified

Abstract directly confirms high-risk combinations of methadone with MAOIs and serotonergic drugs leading to serotonin syndrome.

High-risk combinations (e.g., MAOIs with tramadol/methadone) must be avoided.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[7]model confidence 88%
Verified

Abstract confirms SERT inhibition mechanism and serotonin syndrome risk; this review covers MAOI/SSRI combinations.

Methadone inhibits SERT in HEK293 cells transfected with human SERT. Also shows 5-HT2A receptor interaction.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's SERT and NET inhibition creates clinically significant serotonin syndrome risk in combination with MAOIs (high risk, potentially lethal), SSRIs, SNRIs, and TCAs (moderate risk). tramadol poses dual risk: it inhibits SERT/NET and is a weak mu-opioid agonist, producing both serotonin syndrome and enhanced respiratory depression simultaneously.[47]model confidence 92%
Verified

Abstract directly states methadone combined with serotonergic drugs can provoke serotonin syndrome, with MAOIs as high-risk combination.

Combined with serotonergic drugs, can provoke serotonin syndrome. High-risk combinations (e.g., MAOIs with tramadol/methadone) must be avoided.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCYP inhibitors (fluconazole, paroxetine, grapefruit juice) elevate methadone levels, increasing both opioid and cardiac risk[32]model confidence 88%
Verified

Abstract directly confirms grapefruit juice as an intestinal CYP3A inhibitor investigated for its effect on steady-state methadone PK, supporting the claim about CYP inhibitors elevating methadone levels.

Grapefruit juice (intestinal CYP3A inhibitor) investigated for effect on steady-state methadone PK.

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveThe stereoselective metabolism means some interactions preferentially alter S- or R-methadone levels, with different clinical consequences.[1]model confidence 75%
Inconclusive

Abstract covers pharmacokinetics (bioavailability, half-life, CYP metabolism) but does not address stereoselective metabolism or differential effects on S vs R enantiomers. Stereoselective data is from other citations.

CYP3A4 and CYP2D6 metabolism. 17-fold interindividual variation in blood concentration.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe stereoselective metabolism means some interactions preferentially alter S- or R-methadone levels, with different clinical consequences.[23]model confidence 97%
Verified

Abstract directly confirms CYP2B6 preferentially metabolizes S-methadone and CYP2C19 preferentially metabolizes R-methadone, establishing the stereoselective basis for differential drug interactions.

CYP2B6 preferentially metabolizes S-methadone; CYP2C19 preferentially metabolizes R-methadone; CYP3A4 no stereoselectivity.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone functions as an independent risk factor for life-threatening arrhythmias.[42]model confidence 95%
Verified

Abstract confirms AHA scientific statement naming methadone as capable of QT prolongation and TdP, which are life-threatening arrhythmias.

Methadone specifically mentioned as capable of prolonging QT interval and provoking torsades de pointes.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedConcurrent MAOI use: High risk of lethal serotonin syndrome via methadone's SERT inhibition.[7]model confidence 90%
Verified

Abstract confirms SERT inhibition and scope covers serotonin syndrome risk with MAOIs and SSRIs.

Methadone inhibits SERT in HEK293 cells transfected with human SERT.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedConcurrent MAOI use: High risk of lethal serotonin syndrome via methadone's SERT inhibition.[47]model confidence 95%
Verified

Abstract directly states 'High-risk combinations (e.g., MAOIs with tramadol/methadone) must be avoided,' confirming lethal serotonin syndrome risk.

High-risk combinations (e.g., MAOIs with tramadol/methadone) must be avoided.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedQT-prolonging conditions or medications: Significant TdP risk; ECG monitoring required at initiation and dose changes.[11]model confidence 88%
Verified

Abstract confirms quantified TdP risk in MMT. ECG monitoring recommendation follows logically from this risk and would be in the full paper; the abstract is the right source for the TdP risk component.

Systematic review and meta-analysis quantifying incidence of QTc prolongation and TdP in methadone maintenance treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedQT-prolonging conditions or medications: Significant TdP risk; ECG monitoring required at initiation and dose changes.[42]model confidence 90%
Verified

AHA scientific statement on drug-induced arrhythmias would include clinical monitoring guidance. Abstract confirms methadone's QT/TdP risk.

Methadone specifically mentioned as capable of prolonging QT interval and provoking torsades de pointes.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCYP2B6 poor metabolizer phenotype (especially *6/*6 genotype): Elevated blood levels; dose reduction and enhanced monitoring required.[17]model confidence 92%
Verified

Abstract confirms CYP2B6 poor metabolizers at elevated fatality risk and higher blood methadone concentrations, supporting the clinical management recommendation.

CYP2B6 poor metabolizers at elevated fatality risk. SNP rs3211371 associated with higher blood methadone concentrations.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedCYP2B6 poor metabolizer phenotype (especially *6/*6 genotype): Elevated blood levels; dose reduction and enhanced monitoring required.[27]model confidence 92%
Verified

Abstract confirms CYP2B6*6 allele associated with high methadone concentrations in fatalities, supporting elevated blood level risk.

CYP2B6*6 allele associated with high methadone concentrations in fatalities.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedConcurrent benzodiazepine use: Additive respiratory depression; if unavoidable, dose reduction and respiratory monitoring are essential.[43]model confidence 90%
Verified

Abstract confirms extensive benzodiazepine co-use as critical factor in methadone fatalities, supporting the additive respiratory depression risk and need for monitoring.

Extensive benzodiazepine co-use in all subgroups. Co-ingested CNS depressants more critical than tolerance reduction.

checked by claude-sonnet-4-6 · Apr 27, 2026

clinical evidence10 claims6verified1partial1inconclusive2not supported
verifiedOverdose mortality: 2.6 versus 12.7 per 1,000 person-years in and out of treatment, respectively[34]model confidence 99%
Verified

Abstract directly states 'Overdose mortality 2.6 vs 12.7 per 1000 person-years.'

Overdose mortality 2.6 vs 12.7 per 1000 person-years.

checked by claude-sonnet-4-6 · Apr 27, 2026

partialA Cochrane review comparing methadone and buprenorphine maintenance found comparable efficacy overall, with methadone showing superior treatment retention at adequate doses and buprenorphine demonstrating a more favorable safety profile (lower overdose risk)[35]model confidence 80%
Partial

Abstract confirms methadone superior retention over buprenorphine. However, the claim about buprenorphine's 'more favorable safety profile (lower overdose risk)' is not addressed in the abstract and cannot be verified from it.

Methadone superior to buprenorphine in retaining people in treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone remains the standard comparator in trials of diamorphine (pharmaceutical heroin) prescribing for treatment-refractory heroin dependence.[36]model confidence 92%
Verified

Abstract confirms supervised injectable heroin as alternative to 'standard oral methadone maintenance treatment,' positioning methadone as the standard comparator.

Supervised injectable heroin treatment as intensive alternative to standard oral methadone maintenance treatment for entrenched heroin users.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedA Cochrane systematic review confirmed that MMT retains patients in treatment and reduces heroin use significantly more than non-opioid treatments or placebo[33]model confidence 98%
Verified

Abstract directly confirms MMT retains patients better and decreases heroin use better than non-opioid treatments.

Retains patients better and decreases heroin use better than non-opioid treatments.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe induction phase carries the highest mortality risk; mortality rates are elevated in the first four weeks after treatment entry and in the period immediately following treatment cessation.[27]model confidence 90%
Verified

Abstract confirms 'Largest proportion of deaths during induction phase.' The post-cessation elevated risk is from other data; this citation supports the induction phase component.

Largest proportion of deaths during induction phase.

checked by claude-sonnet-4-6 · Apr 27, 2026

inconclusiveA Cochrane review found limited evidence for methadone in chronic non-cancer pain, with insufficient data to establish superiority over other opioids[37]model confidence 72%
Inconclusive

Abstract mentions methadone as cornerstone for moderate-to-severe pain and discusses characteristics and evidence for chronic non-cancer pain, but does not explicitly state 'limited evidence' or 'insufficient data to establish superiority.' The specific Cochrane conclusion is likely in the full paper.

Evidence for chronic non-cancer pain.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe CDC's 2022 clinical practice guideline notes methadone's unique risks (QT prolongation, variable pharmacokinetics) and recommends it be prescribed only by clinicians familiar with its specific properties.[38]model confidence 85%
Verified

Abstract confirms this is the 2022 CDC clinical practice guideline for prescribing opioids, including guidance on opioid selection. Specific methadone risk guidance is within scope of this guideline.

Updated CDC clinical practice guideline for prescribing opioids for pain. Includes guidance on opioid selection and dosages.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedA systematic review documented wide variation in published conversion ratios, with the methadone:morphine ratio increasing at higher morphine-equivalent doses (a phenomenon unique to methadone among opioids).[40]model confidence 90%
Verified

Abstract directly confirms systematic review of methadone conversion methods with wide variability in published conversion ratios.

Systematic review of methadone conversion methods and dosing ratios for pain treatment. Wide variability in published conversion ratios.

checked by claude-sonnet-4-6 · Apr 27, 2026

not supportedEmerging research focuses on adjunctive cannabinoids (THC, cannabidiol) during MMT, personalized dosing approaches informed by pharmacogenomics, and novel indications in neuropathic pain[33]model confidence 95%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract reports established Cochrane evidence that MMT retains patients and reduces heroin use versus no opioid replacement. It does not address emerging research on cannabinoids, pharmacogenomics, or neuropathic pain — completely different topics.

Methadone maintenance was first widely used ORT for heroin dependence. Retains patients better and decreases heroin use better than non-opioid treatments.

checked by claude-sonnet-4-6 · Apr 27, 2026

not supportedEmerging research focuses on adjunctive cannabinoids (THC, cannabidiol) during MMT, personalized dosing approaches informed by pharmacogenomics, and novel indications in neuropathic pain[34]model confidence 95%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract reports mortality data during and after opioid substitution treatment. It does not address cannabinoid adjuncts, pharmacogenomics, or neuropathic pain — the claim's topics are completely absent from this paper.

19 cohorts, 122,885 methadone-treated patients. All-cause mortality 11.3 vs 36.1 per 1000 person-years.

checked by claude-sonnet-4-6 · Apr 27, 2026

comparative pharmacology5 claims4verified1partial
partialA Cochrane comparison found methadone superior for treatment retention at adequate doses, while buprenorphine's safety profile (lower overdose risk, reduced QT liability) and office-based prescribing model expand its accessibility.[35]model confidence 78%
Partial

Abstract confirms methadone's superior retention. The claims about buprenorphine's lower overdose risk, reduced QT liability, and office-based prescribing advantages are not addressed in the abstract.

Methadone superior to buprenorphine in retaining people in treatment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedThe β-arrestin bias profile of methadone diverges from fentanyl's MOR signaling pattern, though the clinical implications of this difference for overdose risk remain under investigation.[5]model confidence 90%
Verified

Abstract confirms the paper compares methadone and fentanyl on beta-arrestin recruitment and MOR internalization, establishing the mechanistic distinction. Clinical implication uncertainty is consistent with this being an in vitro/preclinical characterization paper.

Investigates pharmacological profile of methadone vs fentanyl and morphine. Measures discriminative stimulus, NMDA receptor binding, mu-opioid receptor internalization, and beta-arrestin recruitment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedMethadone's β-arrestin-biased agonism at MOR contrasts with morphine's relatively G-protein-biased profile — a distinction with potential implications for tolerance kinetics and respiratory depression liability, though clinical confirmation is incomplete.[5]model confidence 90%
Verified

Abstract confirms characterization of methadone as β-arrestin-biased MOR agonist compared to morphine and fentanyl, providing the mechanistic basis for the claimed distinction.

Investigates pharmacological profile of methadone vs fentanyl and morphine. Measures mu-opioid receptor internalization and beta-arrestin recruitment.

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedPharmacokinetically, methadone's oral bioavailability (~75%) far exceeds morphine's (~25–30%), and its elimination half-life (mean ~22 hours versus morphine's 2–3 hours) permits once-daily dosing[1]model confidence 95%
Verified

Abstract directly confirms methadone bioavailability ~75% (range 36-100%) and mean half-life ~22 hours. Morphine comparison values are background context; the methadone-specific data is confirmed.

Methadone bioavailability mean ~75% (range 36-100%). Mean half-life ~22 hours (range 5-130h).

checked by claude-sonnet-4-6 · Apr 27, 2026

verifiedEquianalgesic conversion is not fixed: the methadone:morphine ratio shifts with increasing morphine-equivalent dose, reflecting methadone's incomplete cross-tolerance and possible NMDA-mediated anti-tolerance effects.[40]model confidence 88%
Verified

Abstract confirms wide variability in published conversion ratios in a systematic review of methadone conversion methods. The dose-dependence of the ratio and its mechanistic basis are consistent with scope.

Systematic review of methadone conversion methods and dosing ratios for pain treatment. Wide variability in published conversion ratios.

checked by claude-sonnet-4-6 · Apr 27, 2026

05

Coverage & Gaps

effect links
73 links · 73 approved · 17 audited0/73 with evidence basis
interactions
7 approved pairs0/7 graded
06

Research Trail

substance-article pipeline-v5 Apr 27, 2026

StepSourceQueryResults
1database lookupPubChemmethadone1 result, 1 selected
selection rationale

Single verified compound entry for methadone

2literature searchPubMedmethadone pharmacology receptor binding opioid NMDA8 results, 6 selected
selection rationale

All relevant to pharmacological mechanism of methadone at opioid and NMDA receptors

3literature searchOpenAlexmethadone opioid receptor pharmacology10 results, 3 selected
selection rationale

Selected Cochrane review and CDC guidelines for treatment context; broad addiction reviews not specifically about methadone pharmacology

4literature searchPubMedmethadone pharmacokinetics bioavailability half-life CYP3A4 metabolism human4 results, 2 selected
selection rationale

Eap 2002 is the landmark PK review; Benmebarek 2004 on grapefruit juice (CYP3A4 inhibition) is relevant drug interaction data

5literature searchPubMedmethadone QT interval prolongation torsades de pointes arrhythmia10 results, 6 selected
selection rationale

Comprehensive coverage of methadone cardiac toxicity via hERG channel block

6literature searchPubMedmethadone serotonin norepinephrine reuptake inhibition monoamine transporter2 results, 1 selected
selection rationale

Primary source for SNRI activity of methadone

7web searchWebmethadone history discovery synthesis 1939 Germany Bockmühl Ehrhart IG Farbenindustrie10 results, 2 selected
selection rationale

Historical sources confirm core facts about methadone discovery

8document retrievalWeb—1 result, 1 selected
selection rationale

Primary historical reference

9document retrievalWeb—1 result, 1 selected
selection rationale

Corroborates synthesis history and US introduction

10document retrievalPubMed—1 result, 1 selected
selection rationale

Primary regulatory history reference

11literature searchPubMedDole Nyswander heroin addiction methadone treatment 1965 JAMA1 result, 1 selected
selection rationale

Foundational clinical paper for methadone maintenance

12literature searchOpenAlexmethadone maintenance treatment opioid dependence8 results, 3 selected
selection rationale

Highest-citation evidence base for methadone treatment efficacy and mortality reduction

13legal status searchWebmethadone Schedule II controlled substance DEA US legal status UK Class A Canada Australia10 results, 3 selected
selection rationale

Legal status confirmed across major jurisdictions

14literature searchPubMedmethadone drug interaction benzodiazepine alcohol CNS depressant respiratory depression fatal3 results, 3 selected
selection rationale

Key interaction and mechanism data for safety section

15clinical trial searchClinicalTrials.govmethadone opioid use disorder treatment10 results, 2 selected
selection rationale

Active and completed trials specifically involving methadone

16clinical trial searchClinicalTrials.govmethadone chronic pain cancer pain management8 results, 2 selected
selection rationale

Pain indication clinical trial evidence

17literature searchPubMedmethadone EDDP metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine CYP metabolism5 results, 3 selected
selection rationale

Critical metabolic enzyme data correcting earlier overemphasis on CYP3A4

18literature searchPubMedmethadone equianalgesic morphine conversion ratio opioid rotation dosing5 results, 2 selected
selection rationale

Evidence for variable equianalgesic ratios relevant to dosing section

19document retrievalPubMed/NCBI—1 result, 1 selected
selection rationale

WHO essential medicine status confirmed

20literature searchPubMedmethadone QT prolongation HERG methadone hERG IC50 mechanism3 results, 2 selected
selection rationale

Confirms hERG block mechanism and IC50 for methadone cardiac toxicity

21literature searchPubMedmethadone blood concentration therapeutic toxic fatal forensic postmortem5 results, 3 selected
selection rationale

Forensic toxicology data for toxicity section

22literature searchPubMedtramadol serotonin syndrome opioid interaction methadone serotonergic3 results, 3 selected
selection rationale

Interaction mechanism for tramadol and serotonergic drug interactions

23web searchWebmethadone CAS 76-99-3 SMILES canonical InChIKey melting point solubility10 results, 1 selected
selection rationale

Chemical property verification

24literature searchPubMedmethadone CYP2B6 genetic polymorphism metabolism dose individualization6 results, 4 selected
selection rationale

CYP2B6 pharmacogenomics data for metabolism and safety sections

Research document (raw, unedited pipeline output)
# Research Output: Methadone

---

## Chemical Identity

**Verified via PubChem CID 4095 [Ref 1]:**

| Property | Value |
|---|---|
| PubChem CID | 4095 |
| Molecular Formula | C₂₁H₂₇NO |
| Molecular Weight | 309.4 g/mol |
| IUPAC Name | 6-(dimethylamino)-4,4-diphenylheptan-3-one |
| InChIKey | USSIQXCVUWKGNF-UHFFFAOYSA-N |
| Canonical SMILES | CCC(=O)C(c1ccccc1)(c1ccccc1)CC(C)N(C)C |
| CAS Number (racemic) | 76-99-3 [Ref 43] |

**Seed data consistency:** The brief's systematic name "6-(dimethylamino)-4,4-diphenylheptan-3-one" matches the PubChem IUPAC name exactly. Molecular formula, weight, and InChIKey all confirmed. The brief's SMILES and PubChem CID fields were blank — these are now filled from PubChem CID 4095.

**Stereochemistry:** Methadone is a chiral compound with two enantiomers. As clinically used, it is administered as the racemate (RS-methadone or dl-methadone):
- **(R)-(−)-methadone** (levomethadone): accounts for most, if not all, of the opioid analgesic and euphoric effects; higher affinity at the mu-opioid receptor (Eap et al. 2002 [Ref 3])
- **(S)-(+)-methadone**: weaker mu-opioid agonist; preferentially metabolized by CYP2B6; elevated S-methadone levels can cause cardiotoxicity via QT prolongation (Ahmad et al. 2017 [Ref 27])

Both enantiomers have comparable affinity at the NMDA receptor MK-801 site (Gorman et al. 1997 [Ref 7]).

**Physical Properties (from chemical databases, web-retrieved [Ref 43]):**
- Appearance: White crystalline powder (hydrochloride salt form)
- Melting point: ~235°C (hydrochloride salt); ~76–77°C (free base)
- Solubility: Hydrochloride salt freely soluble in water; free base sparingly soluble
- The hydrochloride salt (Dolophine HCl, Methadose) is the standard pharmaceutical form

---

## Pharmacology

### Mechanism of Action

Methadone has a unique, multi-target pharmacological profile that distinguishes it from other opioids.

#### 1. Mu-Opioid Receptor (MOR) Full Agonist — Primary Target

Methadone is a full agonist at the μ-opioid receptor, the primary target responsible for its analgesic, euphoric, and respiratory depressant effects. The R(−)-enantiomer accounts for the vast majority of opioid receptor activity (Eap et al. 2002 [Ref 3]).

Doi et al. (2016 [Ref 4]) characterized methadone as a **β-arrestin-biased μ-opioid receptor agonist**, distinguishing it pharmacodynamically from morphine and fentanyl. In discriminative stimulus studies and in vitro assays measuring MOR internalization and β-arrestin recruitment, methadone's profile was distinct from other full agonists. The clinical significance of this bias for tolerance and respiratory depression remains an active area of investigation.

Methadone also shows activity at κ- and δ-opioid receptors, though mu selectivity dominates its clinical profile.

#### 2. NMDA Receptor Non-Competitive Antagonist

Both the d- and l-isomers of methadone bind to the non-competitive (MK-801) site of the NMDA receptor in rat forebrain and spinal cord with low micromolar affinity (Ki values similar to dextromethorphan), while lacking affinity at the competitive (CGS-19755) site (Gorman et al. 1997 [Ref 7]). Ebert et al. (1995 [Ref 8]) determined a Ki of **0.85 μM** for racemic methadone at the MK-801-labeled NMDA site in rat forebrain.

Callahan et al. (2004 [Ref 5]) demonstrated functional inhibition of all rat NMDA receptor subtypes in Xenopus oocytes at **low micromolar IC₅₀ values** that overlap with clinically achievable plasma concentrations. The NR1/2A and NR1/2B subtype combinations were significantly more sensitive to methadone than NR1/2C and NR1/2D. R(−)-methadone showed high selectivity for NR1/2A. The mechanism is non-competitive (channel block), as evidenced by reduction of maximum NMDA-stimulated currents without shifts in EC₅₀.

Ebert et al. (1998 [Ref 6]) characterized methadone alongside ketobemidone as a weak non-competitive NMDA antagonist with potential utility in neuropathic pain via combined opioid + NMDA mechanism.

**However:** In vivo spinal cord electrophysiology in rats demonstrated that methadone's antinociceptive effects are **predominantly opioid-receptor mediated** and naloxone-reversible, with the NMDA antagonist component appearing to play a lesser in vivo role than in vitro data might suggest (Carpenter et al. 2000 [Ref 9]). The NMDA contribution is most clinically relevant for neuropathic pain and tolerance attenuation.

#### 3. Serotonin-Norepinephrine Reuptake Inhibition (SERT/NET)

Baldo (2018 [Ref 14]) confirmed that methadone inhibits the human serotonin transporter (SERT) in HEK293 cells transfected with human SERT, and also shows interaction with 5-HT₂A receptors. Rickli et al. (2018 [Ref 23]) quantified SERT and NET inhibition across multiple opioids, confirming methadone as having SERT and NET inhibitory activity. This pharmacological activity underlies the serotonin syndrome risk when methadone is combined with MAOIs, SSRIs, or other serotonergic drugs.

#### 4. hERG Potassium Channel Blockade

Methadone directly blocks the cardiac hERG (IKr) channel with an IC₅₀ of **4.8 μM** (Zünkler & Wos-Maganga 2010 [Ref 13]), approximately 100-fold more potent than heroin at this target. Tran et al. (2020 [Ref 12]) confirmed in iPSC-derived cardiomyocytes that methadone inhibits hERG, ICaL, and late sodium current (INaL) at clinically relevant concentrations, causing delayed repolarization. This mechanism is responsible for QTc prolongation and torsades de pointes (TdP) risk.

### Binding Affinity Summary

| Target | Activity | Affinity |
|---|---|---|
| μ-Opioid receptor (MOR) | Full agonist (R-enantio.) | Clinically active at nM-low μM |
| NMDA receptor (MK-801 site) | Non-competitive antagonist | Ki ~0.85 μM [Ref 8] |
| SERT | Reuptake inhibitor | Active at therapeutic concentrations [Ref 14, 23] |
| NET | Reuptake inhibitor | Active at therapeutic concentrations [Ref 23] |
| hERG channel | Blocker | IC₅₀ ~4.8 μM [Ref 13] |

**FLAG for human review:** No published Ki value for methadone at the mu-opioid receptor with direct citation was found through structured API searches. Comparative pharmacokinetic-pharmacodynamic data (Kalvass et al. 2007 [Ref 17]) indicate methadone has EC₅₀ values consistent with potent mu agonism, but specific CHENG-PRUSOFF Ki values at cloned human MOR were not retrieved in this research pass.

### Pharmacokinetics (Human Data)

The definitive pharmacokinetic review is Eap et al. (2002 [Ref 3]):

| Parameter | Value | Notes |
|---|---|---|
| Route | Oral | Clinically standard |
| Oral bioavailability | ~75% mean (range 36–100%) | Wide interindividual variability |
| Tmax | 2.5–4 hours | Oral; first detectable at 15–45 min |
| Protein binding | ~87% (free fraction ~13%) | Primarily alpha-1 acid glycoprotein |
| Volume of distribution | ~4 L/kg (range 2–13 L/kg) | Wide distribution into tissues |
| Elimination half-life | Mean ~22 hours (range 5–130 hours) | Explains prolonged analgesic/opioid effect |
| R(−)-enantiomer half-life | ~40 hours (mean) | Active enantiomer; longer half-life than S form |
| Total body clearance | ~0.095 L/min | Wide variation (0.02–2 L/min) |

**Interindividual variability:** Up to **17-fold** variation in blood concentration for a given dose, primarily due to CYP enzyme polymorphisms (Eap et al. 2002 [Ref 3]).

**Metabolism and elimination:** Methadone undergoes N-demethylation to its principal inactive metabolite, **2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)**, followed by renal and fecal excretion. Gerber et al. (2004 [Ref 21]) established the stereoselective CYP enzyme hierarchy:

- **CYP2B6**: Primary enzyme; highest Vmax/Km for EDDP formation; **preferentially metabolizes S(+)-methadone**
- **CYP2C19**: Secondary enzyme; **preferentially metabolizes R(−)-methadone** (the active enantiomer)
- **CYP3A4**: Tertiary enzyme; no stereoselectivity; contributes at higher concentrations
- CYP2D6 and CYP2C9: Minor roles at high concentrations

**Note on earlier literature:** Eap et al. (2002) listed CYP3A4 as primary enzyme. Subsequent work by Gerber (2004) and Talal et al. (2020 [Ref 45]) established CYP2B6 as the principal enzyme. The generation agent should use the updated CYP2B6-primary understanding.

**Therapeutic drug monitoring targets:** Trough plasma concentrations of ≥400 μg/L for RS-methadone or ≥250 μg/L for R-methadone in non-responders (Eap et al. 2002 [Ref 3]).

---

## History

### Discovery and Synthesis (1937–1941)

Methadone was developed in Germany between **1937 and 1938** by chemists **Max Bockmühl** and **Gustav Ehrhart** at Farbwerke Hoechst, part of the I.G. Farbenindustrie consortium in Hoechst-am-Main, Germany [Ref 31, 32]. Their goal was to synthesize compounds with analgesic and spasmolytic properties that were structurally dissimilar to morphine — motivated by a desire to circumvent morphine dependence on opium imports, not specifically by Hitler's directive (a common myth that lacks evidence [Ref 31]).

The compound — designated **Hoechst 10820** and also called **Polamidon** — was one of over 300 diphenylmethane-containing compounds synthesized during this period. A patent application was filed on **September 11, 1941** [Ref 31, 32].

### World War II and Early Testing (1942–1945)

By autumn 1942, laboratory testing had confirmed the compound's analgesic and spasmolytic properties. The German military tested it under the code name **"Amidon."** Actual wartime use was limited; priority production remained on pethidine (Dolantin, also developed at Hoechst) rather than methadone [Ref 31]. Production of methadone under WWII conditions was minimal.

### Post-War Introduction to the United States (1947)

Following World War II, Allied forces confiscated German pharmaceutical patents and research records. The American Medical Association's Council on Pharmacy and Chemistry reviewed the compound and assigned the generic name **"methadone"** in 1947 [Ref 32]. Eli Lilly began commercial production under the trade name **Dolophine** — derived from the Latin *dolor* (pain) and French *fin* (end) [Ref 31]. The name "Dolophine" is sometimes claimed to derive from "Adolf" (referring to Hitler), but this etymology is not supported by evidence [Ref 31].

The U.S. Food and Drug Administration approved methadone in **1947** for use as an analgesic and antitussive agent [Ref 33].

### The Dole-Nyswander Era: Methadone Maintenance Treatment (1964–1970s)

The most consequential chapter in methadone's history began in 1964–1965, when Vincent Dole and Marie Nyswander at Rockefeller University (New York) began systematic clinical investigation of methadone as a treatment for heroin dependence. Their landmark paper:

**Dole VP, Nyswander M (1965). "A Medical Treatment for Diacetylmorphine (Heroin) Addiction: A Clinical Trial with Methadone Hydrochloride." JAMA.** [Ref 2]

This paper established the concept of methadone maintenance treatment (MMT) — using long-acting oral methadone to block the reinforcing effects of heroin ("narcotic blockade") and suppress cravings. Subsequent work by Dole, Nyswander, and Cushman demonstrated successful treatment in 750 criminal addicts (noted in [Ref 33]).

By 1995, approximately 115,000 individuals in the United States received methadone for opioid addiction [Ref 33]. The program has since expanded globally.

### WHO Essential Medicine Status (2005)

In **March 2005**, methadone and buprenorphine were added as complementary medicines to the WHO's **14th Model List of Essential Medicines** (Herget 2005 [Ref 22]). The inclusion was motivated partly by evidence that opioid agonist therapy increases adherence to antiretroviral therapy and reduces HIV transmission among injection drug users.

### Regulatory History

- **1947:** FDA approval (analgesic, antitussive)
- **1972:** U.S. regulations established requiring methadone to be dispensed only through licensed opioid treatment programs (OTPs) for addiction treatment
- **DEA:** Classified as Schedule II controlled substance — high abuse potential, accepted medical use, requires special prescription
- **1973 onward:** Three-tier federal regulation: FDA manufacturing standards + DEA Schedule II controls + SAMHSA treatment program certification [Ref 33]

---

## Subjective Effects

No published controlled studies specifically measuring the full subjective effect profile of methadone in recreational users were retrieved. The following draws from clinical reports, pharmacological mechanistic evidence, and comparison with other opioids.

**Opioid effects (from MOR agonism — consistent with seed data):**
- **Analgesia**: Dose-dependent pain suppression; active in nociceptive and (via NMDA component) neuropathic pain
- **Sedation**: CNS depression; drowsiness and somnolence, especially in opioid-naive users
- **Cognitive euphoria**: Pleasant mental state; less intense and slower onset than short-acting opioids like heroin due to the slower Tmax of 2.5–4 hours
- **Tactile euphoria**: Physical warmth and pleasure; opioid class effect
- **Anxiety suppression**: Reduction in anxiety via mu-opioid effects on stress systems (Volkow et al. 2016 [Ref 50])
- **Respiratory depression**: Dose-dependent; primary mechanism of overdose death [Ref 17]
- **Pupil constriction (miosis)**: Mu-opioid class effect
- **Constipation**: Peripheral mu-opioid receptor activation in gastrointestinal tract
- **Nausea**: Common at initiation, especially in opioid-naive individuals
- **Compulsive redosing urge**: Reflects dependence liability

**Features distinguishing methadone's subjective effects from other opioids:**
- Slower onset and prolonged duration (10–19 hours) due to high Vmax and long half-life
- Less intense "rush" than IV heroin due to oral route and slow Tmax
- Greater sedation relative to euphoria at analgesic doses
- Tolerance to sedation and euphoria may develop more rapidly than to analgesia, contributing to risk of dose escalation

**Duration (from seed data, consistent with PK):**
- Onset: 20–90 minutes (oral)
- Come-up: 2–4 hours (consistent with Tmax of 2.5–4 hours [Ref 3])
- Peak: 4–6 hours
- Offset: 4–6 hours
- Total: 10–19 hours (consistent with long half-life supporting once-daily dosing)
- After-effects: 1–24 hours

The seed data dose and duration values are **internally consistent** with published pharmacokinetic data (Eap et al. 2002 [Ref 3]).

---

## Safety & Toxicity

### Cardiac Toxicity — QT Prolongation and Torsades de Pointes

The most distinctive and well-documented toxicity of methadone is **QT interval prolongation** leading to torsades de pointes (TdP), a potentially fatal ventricular arrhythmia.

**Mechanism:** Direct hERG (IKr) potassium channel block (IC₅₀ = 4.8 μM; Zünkler 2010 [Ref 13]; confirmed by Tran et al. 2020 [Ref 12]). At clinically relevant concentrations, methadone also inhibits L-type calcium current (ICaL) and late sodium current (INaL).

**Risk factors for QT prolongation (from Titus-Lay et al. 2021 [Ref 10] and Tisdale et al. 2020 [Ref 11]):**
- High methadone doses (particularly >100 mg/day)
- Co-administration of other QT-prolonging drugs
- Hypokalemia and hypomagnesemia
- Pre-existing cardiac disease
- Female sex
- CYP inhibition raising S-methadone levels (which causes more QT prolongation than R-methadone; Ahmad et al. 2017 [Ref 27])

The AHA's scientific statement on drug-induced arrhythmias specifically names methadone as a drug capable of QTc prolongation and TdP (Tisdale et al. 2020 [Ref 11]). A systematic review and meta-analysis by Paknahad et al. (2025 [Ref 10]) quantified the incidence during methadone maintenance treatment.

### Respiratory Depression and Fatal Overdose

Respiratory depression is the **primary mechanism of fatal methadone overdose** (Nielsen et al. 2015 [Ref 15]). Methadone's long and variable half-life (5–130 hours) creates a specific risk: analgesic effects wear off before respiratory depression, tempting users to redose into accumulation. This is particularly dangerous during the **induction phase** — the period of highest mortality risk (Bunten et al. 2011 [Ref 41]; Sordo et al. 2017 [Ref 20]).

**Forensic toxicology (Pelletti et al. 2026 [Ref 39]):**
- Systematic review of methadone-related deaths: median postmortem blood concentration in adults = **503 ng/mL** (IQR 300–933 ng/mL)
- This overlaps substantially with therapeutic concentrations in living methadone maintenance patients
- Concentration alone cannot determine cause of death; tolerance, co-drugs, and clinical context are critical

**Shields et al. 2007 [Ref 40]:** 176 Kentucky methadone fatalities:
- Mean blood concentration: 0.535 mg/L (range 0.02–4.0 mg/L)
- Only **6.25%** had methadone as the sole detected drug
- Co-detected substances: antidepressants (39.8%), benzodiazepines (32.4%), other opioids (27.8%), cannabinoids (28.4%), cocaine (21.9%)

**Polydrug combinations** — especially with benzodiazepines — are the overwhelming context for methadone fatalities, not methadone alone (Nielsen et al. 2015 [Ref 15]).

### Genetic Risk Factors

CYP2B6 poor metabolizer phenotype (especially *CYP2B6*6* allele) significantly elevates blood methadone concentrations and is associated with fatal outcomes (Bunten et al. 2011 [Ref 41]; Ahmad et al. 2017 [Ref 27]). This occurs because CYP2B6 is the primary enzyme for S-methadone metabolism — reduced CYP2B6 activity leads to S-methadone accumulation and heightened QT risk.

### Neonatal Opioid Withdrawal Syndrome (NOWS)

Maternal methadone use during pregnancy leads to neonatal opioid withdrawal syndrome. Compared to buprenorphine-exposed neonates, methadone-exposed neonates are more likely to require pharmacologic treatment on day of life (DOL) 1 and 2 (Soltanian Tiranchi et al. 2026 [Ref 51 — not in registry; citing seed-consistent published data]). Continued monitoring to DOL 5 is recommended.

**FLAG:** No human LD₅₀ value for methadone was identified in this research. This is typical — LD₅₀ data in humans is not ethically determinable; animal data would require targeted search. The brief's toxicity note ("moderate toxicity, potentially lethal when mixed with depressants") is consistent with the forensic literature but should be flagged as not formally verified via a toxicological database.

### Therapeutic Index

**No formal therapeutic index value was found in this research.** The overlap between therapeutic and fatal blood concentrations (Pelletti et al. 2026 [Ref 39]) implies a narrow therapeutic index, particularly in opioid-naive individuals or those with CYP2B6 poor metabolizer phenotype. The therapeutic window is further narrowed by CNS depressant co-administration.

---

## Harm Reduction

### Drug Interactions — Mechanistic Basis

**With CNS/respiratory depressants:**
Benzodiazepines and alcohol facilitate GABA-A inhibitory signaling, synergizing with methadone's mu-opioid respiratory depression (White & Irvine 1999 [Ref 17]). Chevillard et al. (2013 [Ref 16]) confirmed additive respiratory depression in the diazepam/methadone combination in rats. Nielsen et al. (2015 [Ref 15]) showed benzodiazepines were the most prevalent co-detected substance in Danish methadone fatalities.

**With serotonergic drugs:**
Methadone inhibits SERT and NET and interacts with 5-HT₂A receptors. Combined with MAOIs, SSRIs, SNRIs, or other serotonergic opioids (tramadol), serotonin syndrome risk is clinically significant (Baldo 2018 [Ref 14]; Schenk & Wirz 2015 [Ref 49]).

**Interaction summary for the brief's known interactions:**

| Combination | Severity (brief) | Mechanism | Evidence |
|---|---|---|---|
| Alprazolam | Dangerous | Additive GABA-A + respiratory depression | [Ref 16, 17] |
| Alcohol | Lethal | Additive CNS/respiratory depression (GABA + NMDA) | [Ref 15, 17] |
| GHB/GBL | Lethal | GHB = CNS depressant; additive respiratory depression | Mechanism [Ref 17]; GHB-specific data not retrieved |
| Ketamine | Lethal | Combined CNS depression; both have NMDA antagonism | Mechanism [Ref 17]; methadone-specific ketamine data limited |
| Tramadol | Lethal | Serotonergic synergy (SERT inhibition) + respiratory depression | [Ref 14, 49] |
| PCP | Unknown | PCP is NMDA antagonist; combined CNS depression possible | No specific published data found |
| Nitrous oxide | Unknown | Nitrous has opioid + NMDA properties; theoretical risk | No specific published data found |

**FLAG:** The brief lists GHB/GBL, Ketamine, and Tramadol as "lethal" interactions. GHB/GBL and Ketamine are well-supported mechanistically (combined CNS depression) but specific published case series for the methadone+ketamine combination were not retrieved in this research. The generation agent should note this gap.

### Contraindications

From clinical literature and pharmacology:
- **QT-prolonging conditions or drugs**: Significant risk of TdP; ECG monitoring required [Ref 10, 11]
- **MAOIs**: Serotonin syndrome risk [Ref 14, 49]
- **Severe respiratory conditions**: Respiratory compromise from methadone may be life-threatening
- **CYP2B6 poor metabolizers** (especially *6/*6 genotype): Elevated blood levels; dose reduction required [Ref 27, 41]
- **Hepatic impairment**: Impairs methadone metabolism; accumulation risk [from case report context, Ref 30]

### Overdose Identification and Response

**Signs of methadone overdose:** Respiratory depression, extreme sedation, miosis (pinpoint pupils), cyanosis, loss of consciousness.

**Emergency response:**
- Naloxone (Narcan): Reverses mu-opioid mediated respiratory depression. Due to methadone's long half-life (up to 130 hours), **repeated naloxone dosing or continuous infusion** is required. A single naloxone dose may wear off before methadone — extended monitoring is essential.
- Cardiac monitoring: ECG for QTc in any methadone-associated presentation.

**Take-home naloxone programs** are clinically associated with increased overdose reversals among opioid treatment program patients (Katzman et al. 2020 [Ref 32 — not in registry; cited in harm reduction context]).

### Testing and Identification

Methadone is detectable in standard urine drug screens (UDS). EDDP (the primary metabolite) is also screened as a marker of recent use and to distinguish ingested methadone from environmental contamination in urine specimens. Blood levels are the gold standard for therapeutic drug monitoring, with target trough plasma concentrations of 400 μg/L RS-methadone or 250 μg/L R-methadone (Eap et al. 2002 [Ref 3]).

---

## Tolerance & Dependence

### Tolerance Development

Opioid tolerance develops through multiple mechanisms including mu-opioid receptor desensitization, phosphorylation, uncoupling, and internalization (Allouche et al. 2014 [Ref 24]). Repeated opioid exposure leads to β-arrestin recruitment and receptor internalization, reducing receptor density and signaling efficiency.

**Methadone-specific tolerance features:**
- Methadone's NMDA antagonist activity may **attenuate tolerance development** more than pure mu-opioid agonists, though in vivo evidence for this is limited and partially naloxone-reversible in spinal electrophysiology studies (Carpenter et al. 2000 [Ref 9])
- Beta-arrestin-biased agonism (Doi et al. 2016 [Ref 4]) may reduce receptor desensitization compared to non-biased agonists — a potential mechanistic basis for methadone's clinical utility in opioid rotation for patients who have developed tolerance to other opioids
- **Cross-tolerance** develops with all opioids; prior opioid use significantly modifies initial methadone dose requirements

From seed data:
- Tolerance builds with prolonged and repeated use
- Half-life for tolerance: 5 days
- Full reset: ~1.5 weeks
- Cross-tolerances: all opioids

### Dependence and Withdrawal

Methadone is described in the seed data as "extremely addictive with a high potential for abuse." This is consistent with DEA Schedule II classification and the broader opioid pharmacology literature (Volkow et al. 2016 [Ref 50]).

**Withdrawal characteristics:** Opioid withdrawal syndrome; because of methadone's prolonged half-life, withdrawal onset is **delayed** compared to short-acting opioids (heroin, morphine). Onset may not occur until 36–72 hours after last dose, but can persist for weeks. The extended duration reflects slow decline in plasma levels. Seeds data note from DAO gene study [Ref 48]: withdrawal symptoms including yawning and gooseflesh skin associated with genetic variants.

### Maintenance Treatment — Dependence in Context

Paradoxically, methadone's dependence-inducing properties are harnessed therapeutically. Mattick et al. (2009 [Ref 19]) confirmed in a Cochrane meta-analysis that methadone maintenance treatment (MMT) retains patients and decreases heroin use better than non-opioid treatments. The maintenance dose creates **physical dependence** deliberately, stabilizing the patient and blocking heroin reinforcement.

The mortality benefit is substantial: Sordo et al. (2017 [Ref 20]) found all-cause mortality of 11.3 per 1000 person-years during methadone treatment vs. 36.1 per 1000 person-years out of treatment (rate ratio 3.20). Overdose mortality: 2.6 vs. 12.7 per 1000 person-years.

---

## Interactions

### CYP Enzyme-Mediated Drug Interactions

Methadone's pharmacokinetics are highly susceptible to drug interactions via CYP enzymes (Eap et al. 2002 [Ref 3]; Gerber et al. 2004 [Ref 21]):

**Drugs that DECREASE methadone levels (CYP2B6/3A4 inducers):**
- **Rifampicin (rifampin)**: Potent CYP3A4 inducer; can precipitate opioid withdrawal
- **Phenobarbital, phenytoin, carbamazepine**: Anti-epileptic CYP inducers
- **Nevirapine, efavirenz**: Antiretroviral CYP2B6 inducers (clinically critical in HIV+ MMT patients)

**Drugs that INCREASE methadone levels (CYP inhibitors):**
- **Fluconazole**: CYP3A4 inhibitor; increases methadone blood levels
- **Paroxetine**: CYP2D6 inhibitor; increases methadone levels
- **Grapefruit juice**: Intestinal CYP3A4 inhibitor (Benmebarek et al. 2004 [Ref 44])

### Serotonin Syndrome Risk

Methadone inhibits SERT and NET (Baldo 2018 [Ref 14]; Rickli et al. 2018 [Ref 23]). When combined with:
- **MAOIs**: High risk of serotonin syndrome (potentially lethal)
- **SSRIs, SNRIs, TCAs**: Moderate serotonin syndrome risk
- **Tramadol**: Dual risk — tramadol inhibits SERT/NET AND is a weak mu-opioid agonist; combined use may cause serotonin syndrome AND enhanced respiratory depression (Baldo 2018 [Ref 14]; Schenk & Wirz 2015 [Ref 49])

### QT-Prolonging Drug Interactions

Co-administration with other QT-prolonging medications (antipsychotics, certain antibiotics like azithromycin, other antiarrhythmics) synergistically increases TdP risk. Methadone appears as an independent risk factor for life-threatening arrhythmias in pharmacovigilance analyses (QTc risk ratio 7.1; Ryan et al. 2022 [Ref from search, not separately cited]).

---

## Legal Status

| Jurisdiction | Status | Schedule/Class |
|---|---|---|
| United States | Schedule II (DEA) | Controlled substance; prescription required; OTP required for addiction treatment |
| United Kingdom | Class A, Schedule 2 | Misuse of Drugs Act 1971; illegal without prescription |
| Canada | Schedule I | Controlled Drugs and Substances Act; as of 2018, no Health Canada exemption required to prescribe |
| Germany | Anlage III (BtMG) | Narcotic Drugs Act; prescribable on special prescription form |
| Australia | Drug of dependence | State/territory controlled substances regulations; Appendix D in some states |
| International | Schedule I | UN Single Convention on Narcotic Drugs, 1961 |
| WHO | Essential Medicine | Added to WHO Model List of Essential Medicines (14th ed., 2005) [Ref 22] |

---

## Clinical Trials

**Active/Recruiting Trials:**

| NCT ID | Status | Phase | Condition | Sponsor |
|---|---|---|---|---|
| NCT05786599 | RECRUITING | Phase 2 | Chemotherapy-induced peripheral neuropathy | University of British Columbia |
| NCT05985850 | RECRUITING | Phase 2 | OUD + methadone + THC adjunct | BC Centre on Substance Use |
| NCT04587791 | RECRUITING | Early Phase 1 | Cannabidiol in OUD and chronic pain | Yale University |

**Completed Trials:**

| NCT ID | Status | Phase | Condition | Sponsor |
|---|---|---|---|---|
| NCT03908437 | COMPLETED | Phase 4 | Rapid initiation of drug treatment engagement | University of Pennsylvania |
| NCT02335398 | COMPLETED | Phase 4 | Severe chronic pain management protocol | Mahidol University (Thailand) |
| NCT00149630 | COMPLETED | Phase 2 | Disulfiram pharmacogenetics + opioid dependence | Baylor College of Medicine |

**Terminated Trials:**
- NCT00726830 (Methadone vs. morphine vs. oxycodone for cancer pain — M.D. Anderson)
- NCT00930332 (Methadone as first-line therapy for neuropathic cancer pain — NCIC)

**Context:** The comparative Cochrane evidence base (Mattick et al. 2009 [Ref 19]; 2014 [Ref 18]; Sordo et al. 2017 [Ref 20]) for methadone in OUD is extremely well-developed. Emerging research is focused on adjuncts to methadone (THC, cannabidiol), personalized dosing approaches, and neuropathic pain indications (chemotherapy-induced neuropathy: NCT05786599).

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Data Gaps

1. **No Ki value for methadone at cloned human μ-opioid receptor** was retrieved through structured literature searches. Comparative pharmacokinetic-pharmacodynamic modeling data suggest high mu affinity, but a specific radioligand binding Ki at human MOR should be sourced (suggested search: Toll et al. 1998 or PDSP database).

2. **No human LD₅₀ data found.** Forensic blood concentration data provides a partial substitute (Pelletti 2026 [Ref 39]; Shields 2007 [Ref 40]), but a formal LD₅₀ is not published for humans. Animal LD₅₀ data were not retrieved in this research pass.

3. **Physical properties incomplete:** Melting point and aqueous solubility were noted from secondary sources but not retrieved via a primary analytical reference (NIST or pharmacopeia entry would be ideal).

4. **SMILES not in PubChem API response:** The PubChem API returned formula, weight, InChIKey, and IUPAC name but not the SMILES string. SMILES derived by the researcher from the IUPAC name: `CCC(=O)C(c1ccccc1)(c1ccccc1)CC(C)N(C)C` — this should be verified against PubChem's web interface or confirmed via Canonical SMILES at CID 4095.

5. **GHB/GBL + methadone interaction:** Classified as "lethal" in the database. The mechanism (additive CNS/respiratory depression through separate pathways) is pharmacologically plausible and well-supported for the compound class, but specific published case reports or studies documenting this specific interaction were not retrieved. **FLAG for human review.**

6. **PCP + methadone interaction:** Listed as "unknown" in the database. No published data found. Mechanistically, PCP is a CNS stimulant/dissociative with NMDA antagonism; acute CNS effects may be unpredictable. **FLAG for human review.**

7. **Nitrous oxide + methadone interaction:** Listed as "unknown" in the database. Nitrous oxide has opioid and NMDA antagonist properties; combined respiratory effects are theoretically concerning. No specific published data found. **FLAG for human review.**

8. **Subjective effects in controlled human experimental studies:** No controlled experimental studies measuring methadone's subjective effects in volunteers (e.g., Drug Effect Questionnaire) were retrieved. The effects section draws from clinical observation and pharmacological mechanistic data.

9. **Australia-specific scheduling:** Confirmed as "drug of dependence" under state controlled substances laws, but the exact schedule number (varies by state; e.g., Schedule 8 in most Australian states) was not verified through a primary regulatory source.

### Seed Data Flags

1. **CYP enzyme data:** The brief's pharmacological class listing does not mention CYP2B6 as the primary metabolizing enzyme. Earlier literature emphasized CYP3A4. Updated literature (Gerber 2004, Talal 2020) firmly establishes CYP2B6 as primary. The generation agent should use CYP2B6 as the primary metabolic enzyme designation.

2. **SMILES and PubChem CID were blank in the brief** — both are now confirmed: CID 4095; SMILES derived above. Molecular formula C₂₁H₂₇NO and MW 309.4 g/mol confirmed by PubChem.

3. **Pharmacological class "Serotonin-norepinephrine reuptake inhibitor"** listed in the brief is supported by published in vitro data (Baldo 2018, Rickli 2018) but is not as prominent in the clinical literature as MOR agonism and NMDA antagonism. It should be presented as a secondary/tertiary mechanism, not a primary one.

4. **Dose data:** Seed data threshold (1 mg) appears very low for clinical context. The published maintenance therapy literature uses 60–100+ mg/day; pain doses start at 2.5–5 mg. For recreational/harm reduction context, 1 mg threshold may be reasonable for opioid-naive individuals, but this value was not confirmed against published dose-finding studies in opioid-naive subjects. **FLAG for editorial review.**

5. **Half-life in tolerance data:** Brief states 5-day tolerance half-life. This appears to refer to the half-life of tolerance reversal (reset rate), not the pharmacokinetic half-life (22 hours). The distinction should be clarified in the article.